The genetic basis of multiple sclerosis: a model for MS susceptibility by Goodin, Douglas S
RESEARCH ARTICLE Open Access
The genetic basis of multiple sclerosis: a model
for MS susceptibility
Douglas S Goodin
Abstact
Background: MS-pathogenesis is known to involve both multiple environmental events, and several independent
genetic risk-factors.
Methods: A model of susceptibility is developed and a mathematical analysis undertaken to elucidate the nature
of genetic susceptibility to MS and to understand the constraints that are placed on the genetic basis of MS, both
by the known epidemiological facts of this disease and by the known frequency of the HLA DRB1*1501 allele in
the general populations of northern Europe and North America.
Results: For the large majority of cases (possibly all), MS develops, in part, because an individual is genetically
susceptible. Nevertheless, 2.2% or less of the general population is genetically susceptible. Moreover, from the
model, the number of susceptibility-loci that need to be in a “susceptible allelic state” to produce MS-susceptibility
is small (11-18), whereas the total number of such susceptibility-loci is large (50-200), and their “frequency of
susceptibility” is low (i.e., ≤ 0.12). The optimal solution to the model equations (which occurs when 80% of the loci
are recessive) predicts the epidemiological data quite closely.
Conclusions: The model suggests that combinations of only a small number of genetic loci in a “susceptible allelic
state” produce MS-susceptibility. Nevertheless, genome-wide associations studies with hundreds of thousands of
SNPs, are plagued by both false-positive and false-negative identifications and, consequently, emphasis has been
rightly placed on the replicability of findings. Nevertheless, because genome-wide screens don’t distinguish
between true susceptibility-loci and disease-modifying-loci, and because only true susceptibility-loci are constrained
by the model, unraveling the two will not be possible using this approach.
The model also suggests that HLA DRB1 may not be as uniquely important for MS-susceptibility as currently
believed. Thus, this allele is only one among a hundred or more loci involved in MS susceptibility. Even though the
“frequency of susceptibility” at the HLA DRB1 locus is four-fold that of other loci, the penetrance of those
susceptible genotypes that include this allele is no different from those that don’t. Also, almost 50% of genetically-
susceptible individuals, lack this allele. Moreover, of those who have it, only a small fraction (≤ 5.2%) are even
susceptible to getting MS.
Background
Chronic human diseases such as multiple sclerosis (MS)
often have complex etiological bases [1] and, in general,
both the genetic makeup of an individual and their
environmental experience are critical components of
disease pathogenesis. For example, an individual from
northern Europe or Canada has a life-time MS-risk
[P(MS)] of about 0.1 - 0.2% [2]. The risk in individuals
with an affected family member increases roughly in
proportion to the amount of shared genetic information
between affected relative and the individual [2-9]. Thus,
first degree relatives (50% genetic similarity) such as sib-
lings, parents, and children of an MS proband have a
risk of approximately a 2-5%, second degree relatives
(25% genetic similarity) such as aunts and uncles have a
risk of about 1-2% risk, and third degree relatives (with
12.5% genetic similarity) such as first cousins, have a
risk less than a 1%. By contrast, monozygotic-twins of
an MS proband (~100% genetic similarity) have a risk of
about 25% [2-9]. This proband-wise monozygotic-twin
concordance rate (CRMZ)p r o v i d e sa ne s t i m a t eo ft h e
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stances. The fact that this penetrance is only 25%,
clearly implicates environmental factors in disease
pathogenesis and, in fact, there seem to be multiple fac-
tors involved, each acting at different periods in a per-
son’s life [10]. Nevertheless, as indicated by these
recurrence risks in family members of MS probands,
genetic factors that render certain individuals susceptible
to getting MS also form a critical part of the causal
pathway leading to MS.
To date, the best-established genetic association with
susceptibility to MS is mapped to the chromosomal
region 6p21.3. Within this region, the HLA DRB1 locus
(and especially the haplotype that includes the
DRB1*1501 allele) has the strongest and most consistent
association with MS in both northern European and
North American populations [11-15]. Nevertheless, it is
striking that, even for individuals who carry the HLA
DRB1*1501 allele, only a very small fraction ever
develop MS. This observation seems to implicate the
critical presence other susceptibility alleles at different
locations and, indeed, it seems very likely that genetic
susceptibility to MS is determined by the involvement of
multiple genetic loci scattered throughout the genome.
The present paper explores, through a mathematical
Model and analysis, the nature of this genetic suscept-
ibility to MS. This is not to downplay the importance of
environmental factors in disease pathogenesis, which
were considered in greater detail previously [10].
Neither is it is an exploration of the genes themselves.
Rather, it is an exploration to understand the nature of
susceptibility and to delineate the constraints that are
placed on the genetic basis of MS both by the known
epidemiological facts of this disease and by the known
frequency of the HLA DRB1*1501 allele in the general
populations of northern Europe and North America and
in the MS patients who live in these geographical areas.
Methods
The Nature of the Genetic Model
The definitions for the terms used in the model are pre-
sented in Table 1. The basic epidemiological data used
in model development are presented in Table 2.
For the purposes of the model, it is supposed that
there are (x) independent non-HLA DRB1 susceptibility
locations (i.e., genetic loci that harbor susceptibility
alleles) in addition to the HLA DRB1 location. Each
location may contain more than a single gene (i.e. it
may be an extended haplotype). Thus, in total, there are
(x + 1) susceptibility loci. Moreover, it is supposed that
an individual will be genetically susceptible to MS if
they have an appropriate combination of some number
of these loci in a “susceptible allelic state”.I ft h e yp o s -
sess such a combination, however, having more loci in
“susceptible allelic states” will not affect the resulting
susceptibility despite the fact that this may well affect
the penetrance of MS of specific genetic combinations
in equivalent environmental circumstances. A “suscepti-
ble allelic state” at a specific genetic locus will be said to
exist when the genetic configuration at that locus (i.e.,
its genotype) is such that, either alone or in combination
with “susceptible allelic states” at other locations, the
configuration increases the likelihood that an individual
will develop MS. In order for any specific genetic locus
to be considered a susceptibility locus, it must harbor at
least one such genotype that is determinative for MS-
susceptibility (see below). At any genetic locus, it is pos-
sible that more than one “susceptible” genotype might
exist. In this case the term “susceptible allelic state” will
refer to the presence of any of these genotypes and the
term “frequency of susceptibility” at a particular locus
will refer to the combined (sum) frequency of these gen-
otypes at this locus in the general population. Any com-
bination of “susceptible allelic states” at the different
loci, which results in MS-susceptibility, will be referred
to as a “susceptible genetic combination”.A n ys u c h
combination that does not result in MS-susceptibility
will be referred to as a “non-susceptible combination”.
Naturally, MS does not all have to be genetically-
determined. Thus, it may be that certain sets of environ-
mental events are capable of producing MS regardless of
the individual’sg e n e t i cm a k e - u p .M o r e o v e r ,i ti sa l s o
possible that the development of disease may, in some
circumstances, be a stochastic process and that the dis-
ease is due to only random mechanisms (e.g., unpro-
voked developmental errors), again independent of an
individual’s genetic make-up. Although these non-
genetic mechanisms seem to account for only a small
fraction of the MS cases in the population [10], they
may occur occasionally. Nevertheless, the present analy-
sis, however, is focused on the genetic underpinnings
of MS.
In this conceptualization, susceptibility is understood
to be binary. That is, an individual is either genetically
susceptible or they are not. Nevertheless, within the
group of susceptible individuals, there may be a wide
variation in the likelihood that MS will develop. Such a
binary structure is a direct consequence of the notion
that there exist “susceptibility alleles”, which (either
alone or in combination with other alleles) predispose
an individual to getting MS. Indeed, the HLA
DRB1*1501 allele has been established as just such a
susceptibility allele so that the total number of these
alleles must be at least one. Presumably, there are many
others but, in any case, the total number of susceptibil-
ity alleles must also have an upper bound (i.e., certainly
not every allele in the human genome can be a suscept-
ibility allele). Therefore, the group of individuals who
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Page 2 of 28Table 1 Model Definitions and Abriviations
ah = allelic frequency of the HLA DRB1*1501 susceptibility allele in the general population (only one copy needed for susceptibility)
ahm = allelic frequency of the HLA DRB1*1501 susceptibility allele in the MS population (ahm = 0.328 in UCSF database)
a1,a 2,a 3 = expected allelic frequency of dominant (a1), recessive (a2), and mixed (a3) alleles at the non-HLA DRB1 loci in the general
population
a1m,a 2m,a 3m = allelic frequency of dominant (a1m), recessive (a2m), and mixed (a3m) alleles at the non-HLA DRB1 loci in an MS population
Fi, F = unknown “frequency of susceptibility” (see text for definition) at the non-HLA loci in the general population (i = 1, 2,...x).
[E(Fi) = F = h/r)]
Fm = “frequency of susceptibility” at a non-HLA locus in an MS population
h = known “frequency of susceptibility” at the HLA DRB1 locus in the general population (equal to the probability of having at least
1 copy of this allele) [h = 2ah -( a h)
2 = 0.24]
hm = known “frequency of susceptibility” at the HLA DRB1 locus in the MS population (equal to the probability of having at least 1
copy of this allele) [in the UCSF dataset; hm = 0.55]
Pa1,P a2,P a3 = probability that a person in the general population has a “susceptible allelic state” (see text for definition) at dominant (Pa1),
recessive (Pa2), and mixed (Pa3) non-HLA DRB1 loci. (Pa1 =P a2 =P a3 = F = h/r)
Ph1 = probability that person with an HLA-negative sibling (not an identical- twin) has at least one copy of the HLA DRB1*1501 allele
PH = probability that an individual with an affected HLA DRB1*1501 positive sibling has at least one copy this gene
PA1,P A2,P A3 = probability that an individual will inherit a “susceptible allelic state” given that their sibling is known to be in this state (see text
for definition) at dominant (Pa1), recessive (Pa2), and mixed (Pa3) non-HLA DRB1 loci.
x (x1,x 2,x 3) = number of non-HLA DRB1susceptibility genetic loci involved in MS (dominant loci = x1; recessive loci = x2; mixed loci = x3). [x1 +
x2 +x 3 = x]
PHM = Probability that an individual (from the general population) is both susceptible to getting MS and carries the HLA DRB1*1501
allele. (if Pt1 =P t 0; then PHM =h m)
PAM = Probability that an individual (from the general population) who is both susceptible to getting MS and is in a susceptible state
at a specific non-HLA DRB1 locus. (if Pt1 =P t 0; then PAM =F m)
r = ratio of the “frequency of susceptibility” at the HLA DRB1 locus to the average “frequency of susceptibility” at other non-HLA
DRB1 loci. [r = h/F]
n (n1,n 2,n 3) = number of loci in “susceptible allelic states” required for MS to develop (dominant loci = n1; recessive loci = n2; mixed loci = n3).
[n1 +n 2 +n 3 = n]
P[n] = probability of an individual in the general population possessing at least n loci in a “susceptible allelic state”
C = proportion of patients, susceptible to MS, who do not have any copies of the HLA DRB1*1501 allele
P[S] = probability that an individual in the general population is susceptible to MS This probability is the same as P(G).
Pt = average penetrance of MS phenotype in susceptible patients. Also equal to the proband-wise monozygotic-twin concordance
rate (CRMZ).
Pt* = average penetrance of MS phenotype in susceptible patients, adjusted for the shared intra-uterine and childhood environment
of twins. [Pt* = (Pt) (2.9/5.4) = CRIG] (See text)
Pt1 = average penetrance of MS phenotype in susceptible patients with at least one copy of the HLA DRB1*1501 allele. Also equal to
the proband-wise monozygotic-twin concordance rate (ZH+) for this genotype.
Pt0 = average penetrance of MS phenotype in susceptible patients without any copies of the HLA DRB1*1501 allele. Also equal to the
proband-wise monozygotic-twin concordance rate (ZH-) for this genotype
P(MSH+) = Probability of recurrence (i.e., the recurrence rate) in a family member of an MS proband who has at least one copy of the HLA
DRB1*1501 allele.
P(MSH-) = Probability of recurrence (i.e., the recurrence rate) in a family member of an MS proband who lacks the HLA DRB1*1501 allele.
P(MS) = prevalence of the MS phenotype in the general population (equated to the life-time probability of getting MS)
P(MZ) = Probability of the 1
st twin of an MZ twin-pair getting MS: It is assumed that: P(MZ) = P(MS)
P(MS | MZ) = Conditional probability of getting MS given that your MZ-twin has MS
P(MS | DZ) = Conditional probability of getting MS given that your DZ-twin has MS
P(MS | S) = Conditional probability of getting MS given that your sibling has MS
P(G) = Probability of having any genotype capable of getting MS in response to some environmental exposure
P(E) = Probability of receiving any environmental exposure (all factors) sufficient to cause MS in some susceptible individual
CRMZ = proband-wise monozygotic-twin concordance rate for MS.
CRIG = proband-wise monozygotic-twin concordance rate for MS adjusted for impact of a shared intrauterine environment. [CRIG =
(CRMZ) (2.9/5.4)] This variable is the identical to (Pt*) but is used for clarity of the text.
b’ =C R IG/P(G | IG) = P(MS, G, E | IG)/P(G | IG)
CRDZ = proband-wise dizygotic-twin concordance rate for MS.
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MS (possibly those without any of these alleles), by defi-
nition, would be classified as being genetically non-sus-
ceptible. Any combination of susceptibility alleles that
did not increase the likelihood of MS beyond the rate in
this group would also be classified as genetically non-
susceptible. By contrast, all genetic combinations that
did increase this likelihood would be classified as sus-
ceptible combinations. Therefore, the structure is, of
necessity, binary.
1. Defining and Representing Genetic Susceptibility
For simplicity of the terminology in this section, we will
consider only the situation in which the person is
known to be HLA DRB1*1501-negative (i.e., where [F] is
the expected probability of an individual having a “sus-
ceptible allelic state” at any particular susceptibility
locus). The results of this analysis, however, are easily
generalized to circumstances in which the HLA DRB1
locus is included (Additional File 1; Appendix S1; Sec-
tion 4). Defining the combined “frequency of susceptibil-
ity” at each of the (x) non-HLA DRB1 susceptibility loci
as (Fi) with (i = 1,2,...x), the expected probability that an
individual will have any specific combination of n inde-
pendent loci in a susceptible state is:
EFE F F i
i
n
i
nn [ ( )] [ ( )] [ ] ==
= ∏
1
(1)
where E(Fi) = F for (i = 1,2,...n). Therefore, the use of
the average allelic frequency in calculating the probabil-
ities of different specific combinations of the (x)l o c i
provides an appropriate representation of the different
probabilities.
Because the different genotypes at each of the (n)l o c i
can combine separately with any of those at other loci
to produce susceptibility, it might appear, at first glance,
preferable to consider distinct “susceptibility genotypes”
rather than using their combined frequency at each
locus (Fi) as undertaken above. However, if the i
th locus
has (ki) distinct (i.e., mutually exclusive) “susceptibility
genotypes” and if we define the population frequency of
the j
th genotype at the i
th locus as (fji), then:
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Obviously, this last expression is the same as Equation
(1) and, thus, using the collective frequency (Fi)a te a c h
locus to calculate the expected probability of an indivi-
dual being in a “susceptible allelic state” at each of the n
loci is equivalent to making the same calculation but
considering each distinct genotype separately.
Furthermore, we will let (S) be the set of all genetic
combinations at the x non-HLA DRB1 susceptibility loci
that lead to MS susceptibility. The probability that a
person in the general population is a member of this set
is defined as either P[S] or P(G) depending upon which
terminology is simpler in a given situation. We can par-
tition (S) into disjoint subsets (si), where every combina-
tion that is a member of the subset has, within its
collection of genotypes at the different loci, at least one
group of (si)l o c iw i t h“susceptibility genotypes” that, by
themselves, would result in susceptibility to MS. In addi-
tion, no member of the subset can have a group of
fewer than (si)l o c iw i t h“susceptibility genotypes” that,
by themselves, would lead to MS susceptibility. The
Table 1 Model Definitions and Abriviations (Continued)
ZH+ = proband-wise monozygotic-twin concordance rate for MS when the proband possesses at least one copy of the HLA DRB1*1501
allele.
ZH- = proband-wise monozygotic-twin concordance rate for MS when the proband does not possess a copy of the HLA DRB1*1501
allele.
CRS = concordance rate for the MS phenotype in a non-twin sibling (1
st degree)
CRPC = concordance rate for the MS phenotype in a Parent or Child (1
st degree)
CRAU = concordance rate for the MS phenotype in an Aunt or Uncle (2
nd degree)
CRFC = concordance rate for the MS phenotype in a First Cousin (3
rd degree)
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having this particular combination of “susceptibility gen-
otypes” at the (si) loci is susceptible to getting MS,
regardless of the “allelic state” at any other genetic
locus.
It is nevertheless still possible (and, indeed, likely) that
certain “genotypes” at other genetic loci (either suscept-
ibility or non-susceptibility loci) will influence the pene-
trance of MS of any such group of (si) genotypes in
equivalent environmental circumstances. However, if the
“allelic state” at another locus (or other loci) is determi-
native for the combination of (si) genotypes to result in
susceptibility, then this collection of genotypes would
belong either to the (s(i+1))s u b g r o u po rt oa ne v e n
higher-order subgroup depending upon how many
genes were involved and their exact relationship to sus-
ceptibility. For example, if a particular genotype at
another locus completely nullified the effect of a certain
combination of (si) genotypes, then the presence of a
“susceptibility genotype” at this other locus (i.e., any
genotype other than the one that has this impact) would
also be required for the (si) combination to result in
susceptibility. In this example, then, the combination of
(si) genotypes being considered would actually belong to
the (s(i+1)) subgroup. It is also possible that a certain
“genotypes” or combinations of “genotypes” could both
alter the penetrance of some specific (si) combinations
and, yet also, be determinative for other combinations.
In this case the group of (si) “susceptibility genotypes”
would still be in the (si) subgroup as long as the pene-
trance of their combination with these other “allelic
states” remained greater than the penetrance of a non-
susceptible combination. Genetic loci with alleles or
combinations of alleles at several loci that only modified
the penetrance of other combinations (but were never
determinative for any combination) would not be
included among the x non-HLA DRB1 susceptibility loci
and, therefore, would not be constrained in the Model.
At any specific susceptibility locus, it is possible either
that a particular susceptibility gene has more than one
susceptibility allele, or that the locus harbors more than
one susceptibility gene, or both. Moreover, it is also pos-
sible that some of these susceptibility alleles or genes
(when they occur in combination with genes or alleles
at other loci) will belong to different (si)s u b g r o u p s .
Regardless of the complexity of these interactions, how-
ever, every combination of “susceptibility genotypes” at
the x non-HLA DRB1 susceptibility loci will be uniquely
classifiable either into one of the different (si) subgroups
or into the group of genetic combinations that do not
result in susceptibility to MS.
We will let (yi) be the subset of all possible genetic
combinations with at least (i) of the (x)l o c ib e i n gi na
“susceptible allelic state”. The probability that an indivi-
dual genotype is a member of the (yi) subset is:
P y x x-k k F -F i
kx - k
ki
x
[ ] [( )!/( )!( )!][ ] [ ] =
= ∑ 1 (2)
If we define (Pi) as the probability that any member of
this (yi)s u b s e ta l s ob e l o n g st ot h e( s i) subset, then the
probability of an individual genotype being a member of
the (si) subset is:
Ps P Py ii i [] [] =⋅ (3)
If we define the k
th summand of the (yi)s u b s e tt ob e
(Pk), and we define (Pki) to be the probability that a
genetic combination within this k
th summand belongs
to the (si) subset, then:
Px x - k k F - F k
kx - k = [( )!/( )!( )!][ ] [ ] 1
And, Equation (3) can be re-written as:
P[s P x x-k k F -F
PP
ii
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[( ) ( )]
=⋅
=⋅
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=
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i i
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∑
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Although one possibility is that (Pki =P i) for all values
of (k) in Equation (4), this need not be the case. Never-
theless, because, for each (k), the value of (Pk) is a con-
stant for defined values of (x) and (F), therefore:
Table 2 Epidemiological Data Used in the Model
‡
Population Men Women
Prevalence of MS [P(MS)] * 150 71.4 228.6
MZ twin Concordance (CRMZ) * 25% 6.5% 34.0%
Raw% Susceptible [P(MS)]/CRMZ)* 0.6% 1.1% 0.7%
Corrected% Susceptible** 1.1% 2.0% 1.3%
% HLA DRB1*1501 (General Population) * 24%
% HLA DRB1*1501 (MS Population) * 55%
Homozygous DRB1*1501 (General
Population)
†
1.6%
Homozygous DRB1*1501 (MS Population)
† 10.0%
‡ For estimated recurrence risks in 1
st,2
nd,a n d3
rd degree relatives; see
Table 12
For estimated recurrence risk in HLA DRB1*1501 positive and negative
patients; see Table 3.
* From Canadian Data [11], based on prevalence of 150/100,000 population
[16] and split into men and women according to [17]. HLA data: D Sadovnick
(personal communication)
** Percent of the population genetically susceptible to susceptible to MS [P
(MS)]/CRMZ] corrected (see text) for the reported [11] difference in
concordance risk for DZ twins (5.4%) and non-twin siblings (2.9%)
† UCSF Database: J Oksenberg (personal communication)
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Consequently, from Equations (3) and (5), it follows
that:
E P P for each value of  k  and  i ki i ([ ] ; ( ) ( ) =
We will let (d) represent the smallest number of loci
(s(d) ≥ s1) that, when combined together in “susceptible
allelic states”, result in genetic susceptibility to MS (i.e.,
every individual with fewer than this number of involved
loci will not be genetically susceptible). Furthermore, we
w i l ld e f i n e( N )s u c ht h a t( d+N≤ x) represents the
smallest number of loci that, when combined together
in “susceptible allelic states” (s(d+N) ≤ sx), will always
result in genetic susceptibility (i.e., every individual with
this number of loci or more will be genetically suscepti-
ble). Thus, (Pi =0 )f o ra l l( s i <s (d))a n df o ra l l( s i >
s(d+N)). In this circumstance, the expected number of
loci required to be in a “susceptible allelic state” (E[si])
will be:
Es i Ps i P Py ii
id
dN
ii
id
dN
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and where:
EPy Py N ii
id
dN
([ ] ) ([ ] / ) =
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Naturally, because E(P[yi]) is a weighted function
using different integer values of [yi], it may not corre-
spond to any integer value. Therefore, the value of the
integer (n) will be assigned such that the condition
E(P[yi]) ≈ P[n] is most closely approximated. Thus:
EPy Pn Py in ([ ] ) [] [ ] ≈=
In this case, one of two conditions will hold. Thus,
either:
([ ([ ] ) [] ([ ] ([ ] ) [] ) Pn 1 ] EPy Pn Pn - 1 EPy Pn ii +> > < < or
depending upon the value of (E(P[yi]). Because the
large majority of individuals are not susceptible to
MS [10], it must be the case that {E(si)>x·F } ,w h e r e
[x · F] is the average number of loci in a “susceptible
allelic state” possessed by a random individual in the
general population.
In this circumstance, then, it is also the case that:
(( ) ) dE s n i ≤≤
with the exact relationship depending upon the spread
(N) of the different genetic configurations that result in
MS susceptibility. Therefore, using n in the estimating
equations will tend to over-estimate the expected num-
ber of susceptibility alleles required for susceptibility
and will provide an upper bound on the average number
involved. In addition, it is noteworthy that:
EP EP i
i
x
i
id
dN
() ()
==
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This follows because, for every (i < m), the expectation
is that (Pi)o ft h e( y m) possible combinations will belong
to the (si) subgroup. At (m = d + N), all genetic combi-
nations, including those belonging to (s(d+N))s u b - g r o u p ,
will result in susceptibility. Therefore, at this point:
EP EP EP dd d N ()( ) ( ) () ( ) ( ) ++ + = ++ 1 1 
Also:
E P E P N ; and therefore: N E(P ii i
id
dN
() ( () / ) =⋅ =
=
+
∑ 1
The total probability of an individual being susceptible
(P[S]) will be:
PS Ps N EPs N EP Py i
id
dN
ii i [] {} ({} ) ( [ ] ) == ⋅ = ⋅ ⋅
=
+
∑
If (P[yi]) and (Pi) are independent (as seems reason-
able because no distribution assumptions have been
made), then it follows that:
EPs EP Py EP EPy ii i ii ( { }) ( [ ]) ( ) ( [ ]) =⋅ = ⋅
and:
PS ] N EP E ( Py EP [ y Pn ii [( ) [ ] ) ( ] ) [ ] =⋅ ⋅ = ≈ i (6)
As before, one of two conditions will hold. Thus,
either:
Goodin BMC Neurology 2010, 10:101
http://www.biomedcentral.com/1471-2377/10/101
Page 6 of 28([] ([] ) [ ] ) ([ ] ([] ) [] ) Pn PS Pn Pn - PS Pn ≥> + >≥ 11 or
must be true depending upon the value of (E(P[yi]).
Therefore, in these circumstances, assuming that
exactly (n) loci are involved and that each of (yn)g e n o -
types confers susceptibility provides an appropriate
representation for the entire distribution of susceptibility
genotypes. However, in contrast to (n), which tends to
overestimate (E[si]), the value of (x) derived from the
exclusive use of P[n] in the calculations will accurately
estimate the total number of loci involved in MS sus-
ceptibility because P[n] is an accurate representation of
the total probability of susceptibility, even in circum-
stances where the susceptibility structure is quite
complicated.
The circumstances considered above (i.e., where N · E
[Pi] = 1) are clearly applicable if each locus harbors only
a single susceptibility allele. However, in the circum-
stances where some loci have more than one susceptibil-
ity allele for a single susceptibility gene, or where some
loci contain more than one susceptibility gene, it is pos-
sible that some specific genetic combinations will not
result in susceptibility even when all (x)l o c ia r ei na
“susceptible state”. In this case, (N · E[Pi]<1 ) ,a n dw e
would need to define an apparent expectation {E’(P[yi])]}
as:
E ’Py EPy N EP ii i ([ ] ) [([ ] ) ] / [ ( ) ] =⋅
so that Equation (6) would become:
PS N EP E ’Py EPY Pn ii i [] ( ) ([ ] ) ([ ] ) ] [] =⋅ ⋅ = ≈
Thus, the only impact of this circumstance would be
to decrease the estimate of (n).
2. Estimating the Proportion of “Genetic” MS in the
Population
It is envisioned that the development of MS might occur
via different pathogenetic mechanisms, with the life-time
probability of developing the MS being defined as P(MS)
and with this probability being equated with the preva-
lence of disease. In the general population, it should be
possible to divide MS cases into two broad categories -
those cases that developed MS through “genetic”
pathways and those that developed MS through “non-
genetic” pathways. In this context, the term “genetic”
MS is used to indicate that the development of MS has
occurred through a pathway requiring both a susceptible
genotype (G) and specific environmental events (E).
Although it is possible that some cases of MS are purely
genetic (i.e., don’t require an environmental trigger) this
seems likely to be rare. The main reasons for this are
that the incidence of MS seems to be increasing in
many places around the world, especially in women
[10,16,17] and that MS was either unheard of or extre-
mely rare before the 19
th century [2,18]. Because purely
genetic MS should have remained relatively constant in
prevalence over such a short time-period (i.e., human
genetics wouldn’t be expected to change this quickly),
these observations suggest that purely genetic MS is not
a major contributor to MS at present.
Rather, the “genetic” form of the disease is envisioned
to develop because a genetically susceptible individual
(in the sense defined above) experiences a set of envir-
onmental events that are sufficient to cause MS given
their particular genotype. The probability that an MS
case in the general population has developed their MS
through this route will be defined as P(MS, G, E), the
probability that an individual in the general population
is genetically susceptible will be defined as P(G), and the
probability that an individual in the general population
will experience a sufficient set of environmental events
to cause MS in a susceptible person will be defined as
P(E). In this formulation, the terms P(G) and P(E) are
conceptualized very broadly. Thus, P(G) refers to the
probability of possessing any genotype that could possi-
bly develop MS through the “genetic route” under some
set of environmental exposures. Similarly, P(E) refers to
the probability of experiencing any environmental expo-
sure that could possibly produce MS under some
selected set of genetic preconditions. As discussed ear-
lier, P(G) is the same as P[S]. Second, the disease may
develop because an individual experiences either a spe-
cial set of environmental events (E**) that are sufficient
to cause MS in anyone (i.e., independent of their genetic
make-up) or through a set of purely stochastic events
(e.g., random, unprovoked, errors during development).
The life-time probability that an individual will develop
MS by the “genetic” route is termed P(MS, G, E),
whereas the corresponding probability for all combined
forms of “non-genetic” MS is termed P(MSE).
Thus, the starting equation is:
P(MS) P(MS,G,E) P(MSE)
P(MS,G,E) P(MSE) 15
=+
= *. − 00 0
(7)
where (0.0015) is chosen because it is the mid-point of
the estimated prevalence range for MS in Canada (i.e.,
0.1-0.2%). Because both P(MSE) and P(MS, G, E) must
be (≤0.0015), the cross-product term (the probability of
getting MS through both routes) is negligible compared
to the other two terms and can be ignored. Similarly, as
discussed above, any contribution from purely genetic
MS (i.e., not requiring an environmental trigger) will
also be ignored.
In this circumstance, if we can define the proportion
(p) as:
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so that Equation (7) can be rewritten as:
PM S PM S G E PM S E
pP M S 1 pP M S 1 5
() = () + ()
= () ( ) +− () ( ) =
,,
** . 00 0
(8)
The value of (p) can be estimated from two indepen-
dent epidemiological observations. However, before con-
sidering the implications of these observations, one
fundamental assumption is required. If the term P(MZ)
is used to represent the life-time probability that the
first twin of a monozygotic (MZ) twin-pair will get MS,
then the necessary assumption is that this probability is
the same as that for any other member of the general
population. Stated explicitly, this assumption is that:
PM Z PM S () = ()
Intuitively, this assumption seems reasonable, espe-
cially given the facts that there is no genetic propensity
to having MZ twins, that twins not over-represented in
MS populations and, finally, that MS is not over-repre-
sented in twin populations [11]. These observations are
especially compelling considering the fact that almost all
cases of concordant MS, whether in MZ twins, in dizy-
gotic (DZ) twins, or in siblings, represent individuals
who have developed MS through the genetic route. To
demonstrate this, it is clear from above that:
PM S E 1 5 () < 00 0 .
Moreover, because, by definition, P(MSE) is indepen-
dent of the genetics, then:
PM S E | S PM S E () ( ) =
Therefore, the conditional probability that a sibling (S)
of an MS proband will get MS can be expressed as:
PM S E | S 2 9
P MS G E|S P MSE|S
PM S G E | S 1
,.
,,
,, .
() =
= () + ()
< () +
00
00 0 5 5
and, thus, that:
P MS G E|S 95 P MS E|S ,, . * , () > () ( ) 0 (9)
This percentage increases to much more than 95%
when a more realistic estimate for P(MSE) is used. The
same conclusion also applies to concordant MZ twins,
in whom the observed concordance rate is considerably
higher (0.25; see Table 2). Using this information,
together with the fact thatt h ep e n e t r a n c eo fM Si s
essentially the same in patients regardless of weather
they carry the HLA DRB1*1501 allele (Table 3), leads to
the estimate that (p = 0.92) or that 92% of MS patients
have developed their disease through the genetic route
[10].
The second observation suggesting that the large
majority of MS has developed through the genetic route
comes from a population based cohort study in Finland
[19]. This study includes 3,083 monozygotic twin-pairs
born prior to 1957. These authors reported that in 21 of
these pairs, at least one twin had MS and, of these, 10
pairs (3 concordant for MS) agreed to participate in the
study. This observation leads to the estimate of:
P MS G E 3 21 1 1 3 83 2 4 per 1  populati ,, / /, , () >() ( ) ( ) = 0 0 0 00 000 o on
which, as pointed out previously [10], greatly exceeds
the reported prevalence of MS in the general population
of Finland [20].
Consequently, both of these observations suggest that
the large majority of MS (perhaps all) occurs by the
route of genetic susceptibility together with an appropri-
ate environmental exposure and, therefore, suggest that
the assumption (p ≈ 1) is a reasonable approximation.
In this circumstance:
PM S E PM S G E
PG PE | G PM S | G E
,, ,
*(,
() ≈ ()
= () ( )( )
(10)
and:
PG PM S G E PM S E | G () = () () ,, / , (11)
or:
PG PM S E PM S E | G () ≈ () ( ) ,/ , (12)
each of which follows directly from the definitions of
different conditional probabilities. Moreover, even in the
circumstance where (p < 1), the estimate for P(MS, G,
E) will become smaller so that the estimated proportion
of the population who are genetically susceptible will
also become smaller.
The conditions leading to Equation (9) are even more
applicable to the circumstances of a monozygotic twin
of an MS proband.
Therefore:
CR P MS E|MZ P MS G E|MZ MZ ,, , = () ≈ () (13)
This estimate is referred to as the proband-wise (or
case-wise) concordance rate [21]. The relationship
between P(MS, E | MZ) and P(MS, E | G) needs to be
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shared intrauterine or early postnatal environment on
the likelihood of MS. Fortunately, this environmental
impact can be estimated from existing data. Thus, as
noted earlier [10,11], the 5.4% recurrence risk for MS in
dizygotic twins (CRDZ) of an MS proband is substan-
tially higher than the 2.9% recurrence risk in non-twin
siblings (CRS). Consequently:
CR CR CR CR
54 2 9 CR 186 CR
DZ DZ S S
SS
/
./. .
=() ( )
=() () = ()
(14)
Because several experimental studies have failed to
identify any differences in MS risk among adopted indi-
viduals, conjugal couples, brothers and sisters of differ-
ent birth order, and in siblings and half-siblings raised
together or apart [22-27], this difference between dizy-
gotic twins and siblings presumably reflects only the
impact of a shared intra-uterine or early post-natal
environment on MS risk [10]. Therefore, because the P
(G) term is the same for both twin and non-twin sib-
lings, then:
CR P MS E G|DZ P G|DZ P MS  E|DZ G
186 P G|S
DZ ,, * , ,
.* *
≈ () = () ( )
= () () P PM S E | S G ,, ()
(15)
Where the different conditional probabilities are
defined for the dizygotic (DZ) and sibling (S) cases in
the same manner as terms of Equation (13) were
defined for the MZ case. Moreover, as discussed above,
there seems to be no change in the risk of environmen-
tal exposure due to siblings sharing their childhood
environment with the MS proband compared to the
same risk in siblings growi n gu pi na ne n v i r o n m e n t
experienced by unrelated individuals in the general
population [22-27]. Similarly, there seems to be no
change in the risk of environmental exposure due to an
unrelated individual sharing their childhood environ-
ment with an MS proband compared to their risk grow-
ing up in the general population. Thus, it seems that the
observed difference in MS risk between non-twin sib-
lings and members of the general population is related
to their genetic make-up [i.e., the P(G | S) or P(G | DZ)
term] and not their environmental exposure terms.
Because:
PG | S PG | D Z () = () (16)
Then, from Equation (15):
P M SG | D ZG 1 8 6 P M SE | SG ,, . * , , () = () ( ) (17)
Using this same estimate to adjust for the impact of a
shared intra-uterine and early post-natal environment
on the identical genotypes (IG) shared by monozygotic
twins, using Equation (13), yields:
PM S G E | M Z C R MZ ,, () ≈
so that:
CR 186 P MS G E|IG MZ .* , , ≈ () ( ) (18)
Using Equation (18), we can define an adjusted mono-
zygotic concordance rate (CRIG), removing the intrauter-
ine and early postnatal environmental effects as:
CR P MS G E|IG
CR 186 25 186 134
IG
MZ
,,
/. . /. .
= ()
== = 00
(19)
Finally, we note that:
P MS G E|IG P G|IG P MS E|IG G ,, * , , () = () ( )
Table 3 MS Concordance rates in Monozygotic Twins of HLA DRB1*1501-positive (ZH+) and HLA DRB1*1501-negative
(ZH-) Probands*
Monozygotic Twins of MS Probands
HLA DRB1*1501 Positive HLA DRB1*1501 Negative Totals
Concordant for MS (C) 91 1 2 0
Discordant for MS (D) 31 42 73
Totals 40 53 93
Pair-wise Concordance
† ZH+ = (9/40) = 23% ZH- = (11/53) = 21%
Proband-wise Concordance
†† ZH+ = 31% ZH- = 29%
Proband-wise Concordance (Adjusted)
††† ZH+ = 17% ZH- = 16%
* Data derived from: Willer et al., 2003 [11].
† Pair-wise rates calculated as (Z = C/(C + D).
†† Proband-wise concordance rates calculated as (Z = 2C/(2C + D) adjusted [21] for the overall probability of doubly ascertaining concordant twin-pairs (54%) in
the Willer, et al., 2003 [11] study.
††† See Text, Equation (20).
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b’= () =
= () ( )
CR P G|IG
P MS E|IG G P G|IG
IG /
,, /
(20)
However, because we are disregarding any contribu-
t i o nf r o mp u r e l yg e n e t i cM S( s e ea b o v e ) ,a n dw ea r e
assuming that (p ≈ 1) then:
P E|MS 1 and: P G|IG 1 () ≈ () ≈ ; (21)
so that:
PM S E PM S , () ≈ ()
In this circumstance:
b’ = () P MS|IG G , (22)
Moreover, because:
PG PM S G PM S | G () = () () ,/
so that:
PG PM S PM S | G () ≤ () ( ) / (23)
If:
p 1 and  if also: P MS|IG G P MS|G ;, , ≈= () ≈ () b’
T h e n ,c o m b i n i n gE q u a t i o n s( 1 2 ) ,( 1 8 ) ,( 1 9 ) ,( 2 2 ) ,a n d
(23), in this circumstance, yields:
PG PM S E
P MS 15 134 11
() ≈ ()
≈ ()==
,/
/./ . . %
b
b
’
’ 00 0 0
(24)
3. Estimating the Prevalence of Genetic Susceptibility to MS
Initially, we will divide the various susceptibility geno-
types are grouped into two mutually exclusive subsets
based on their penetrance. The first group (G1) will be
defined as those genotypes with an expected penetrance
as high or higher than average, whereas the second
group (G2) will be defined as those with an expected
penetrance as low or lower than average. [Genotypes
with an average penetrance are divided evenly between
G1 and G2.] Furthermore, we will define P(G1) and P
(G2) as the probabilities of these two different classes of
genotype in the general population so that:
PG PG 1 PG 2 () = () + () (25)
We will define the (i
th) susceptibility genotype in (G1)
as (Gi) so that:
EPM S E G PM S E G 1
PG PM S E | G 1
i ,, ,,
*,
, () {} = ()
= () ( )
Therefore, the average penetrance of the (G1) subset
is:
PM S E | G 1 , ()
Or in circumstances of Equation (21):
P MS E|G1 P MS|G1 , () = ()
By the definition of the G1 and G2 subsets, and from
Equation (16), it must be the case that:
PM S | G 1 PM S | G 2 () ≥ () (26)
Moreover, in order for these two quantities to be
equal requires that the variance in the quantity P(MS |
G, E) to be zero. However, if the variance is not zero,
then, in moving from the susceptible population to the
MS population (or to the MZ twin population where
one twin is known to have MS), there must be an
enrichment of the more penetrant (G1) genotypes in
comparison to the less penetrant (G2) genotypes. There-
fore, it must be the case that:
b’ , = () ≥ () P MS|IG G P MS|G (27)
Consequently, from Equations (23) and (27), it must
be the case that:
PG PM S G () ≥ () ,/ b’ (28)
When:
p1 t h e n PG 1 PG : = () = ()
all genotypes have the same penetrance and, therefore:
PG PM S G () = () ,/ b’
so that:
b’ ,/ , = () ( ) = () = () PM S G PG PM S | G PM S | I G G(29)
If we define (p’) as:
p ’ PG PG 1 () () = () * (30)
so that:
() * 1p ’P G P G 2 − () = () (31)
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PM S G PG 1 PM S G p ’PG
P MS|G p’
,/ ,/
/
() ( ) = () ( ) ( )
= ()
(32)
Because, from Equation (28), at (p’ = 1):
PM S G PG 1 ,/ () ( ) =b’
It is apparent from Equation (31) that, as (p’)
decreases, the value of {P(MS, G)/P(G1)} increases.
Therefore:
PM S G PG 1 ,/ () ( ) ≥b’ (33)
and:
PG 1 p PG PM S G () =() () ≤ () ’* , / b’
or:
PG PM S G p () ≤ () {} () ,/ / ’ b’ (34)
A similar analysis for the (G2) subset leads to the con-
clusion that:
PG PM S G 1 p () ≤ () {} ,/ / ( – ’ ) b’ (35)
This imposes two simultaneous constraints of the pos-
sible value that P(G) can take. Moreover, it must be the
case that one of the following three statements is true:
p5 p 5 o r1 p 5 ’. ; ’ . ; : ’ . => − () > 00 0
Therefore, these two constraints require that:
PG 2 PM S G
2P M S 2 2
() ≤() ( ) {}
≤() ( ) {} =
*, /
*/ . %
b
b
’
’
(36)
Consequently, based on the epidemiological evidence
from Canada, at most, only 2.2% of the population is
genetically susceptible to getting MS under any
circumstance.
4. Total Number of Susceptibility Loci and Number
Necessary
As discussed and developed in Section 1, for the pur-
pose calculating the expected occurrence of MS in dif-
ferent circumstances, the complex genetic susceptibility
structure envisioned can be appropriately represented
using the expected “frequency of susceptibility” and,
also, by considering that any combination of a fixed
number (n) of susceptibility loci (in a “susceptible allelic
state”) leads to susceptibility. The estimated prevalence
of HLA DRB1*1501-positivity (i.e., the likelihood of an
individual possessing at least one copy of this allele) in
the general population of Canada is approximately 24%
whereas, in the MS population, this number is increased
to approximately 55% (Table 3). These numbers are
quite similar to other reports from other North Ameri-
can and northern European populations [2,11-14] and
are very similar to the large sample collected at UCSF
(J Oksenberg, personal communication). The HLA
DRB1*1501 allele (like many other alleles) exists on an
extended haplotype in linkage disequilibrium in these
populations so that distinction of one gene from another
on the haplotype has proven difficult [28-30]. Using the
Hardy-Weinberg equilibrium equation for the general
population, the probability (h) that any individual carries
at least 1 copy of the HLA DRB1*1501 extended haplo-
type is:
–. h2 a 1a a 2 a a 2 4 hh h
2
hh
2 =− () += = 0 (37)
From this expression, the allelic frequency (ah)c a nb e
calculated and is (ah = 0.128).
At each genetic locus, the “frequency of susceptibil-
ity” represents the probability that a random individual
in the general population will be in a “susceptible alle-
lic state” at a particular genetic locus. Definitions for
the different types of susceptibility loci (dominant,
recessive, or mixed) are presented in the Additional
File 1 (Appendix S1; Section 1). In the case of a “domi-
nant” susceptibility allele (or alleles), the “frequency of
susceptibility” is the probability that an individual in
the general population has at least one copy of this
allele (or these alleles). For simplicity, at the HLA
DRB1 location, the “frequency of susceptibility” (as
indicated above) will be approximated by the known
value of (h). This, of course, ignores contributions to
susceptibility from other HLA DRB1 alleles [12]. How-
ever, as a rough approximation, this simplification
seems reasonable. In the case of a “recessive” suscept-
ibility allele (or alleles), by contrast, the “frequency of
susceptibility” is the probability that an individual in
the general population has two copies of this allele. If
there are two or more different recessive alleles, the
heterozygous state (i.e., the possession of two different
“recessive” alleles) may or may not confer susceptibility
(see Additional File 1; Appendix S1; section 5). In the
case of “mixed dominance” alleles, the “frequency of
susceptibility” will be the sum of these “dominant” and
“recessive” frequencies. We will let (Fi)b et h e“fre-
quency of susceptibility” at the i
th non-HLA DRB1
location and we will define (r) as an unknown positive
constant such that the mathematical expectation (E) of
(Fi)i s :
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Thus, the constant (r) relates the expected (but
unknown) “frequency of susceptibility” at these non-
HLA DRB1 locations to the known “frequency of sus-
ceptibility” at the HLA DRB1 locus and (F) reflects the
average of these individual “frequencies of susceptibil-
ity” for the different susceptibility loci. The constant
(r) is of no importance in itself. Rather, it is used as a
convenience to permit the expected “frequency of sus-
ceptibility” to be varied over the entire range of possi-
ble values (i.e., from near 0 to near 1) and expressed
in terms of the known value of (h). Naturally, because
each locus (haplotype) will typically consist of several
genes, it is possible that there may be more than one
susceptibility gene at any one locus and it is also possi-
ble that there may be more than one susceptibility
allele for any single gene within the locus. The impact
of both these circumstances is considered in the Addi-
tional File 1 (Appendix S1; Section 5). For developing
the model initially, however, in both the “dominant’
and “recessive” cases, the only the circumstance that
will be considered is that in which each genetic locus
harbors only a single susceptibility gene and that gene
has only a single susceptibility allele. In the “mixed
dominance” case, each locus will be presumed to have
just two susceptibility alleles. As shown in the Addi-
tional File 1 (Appendix S1; Section 5), the derived
model is broadly applicable and, importantly, because
the “frequency of susceptibility” is completely indepen-
dent of these complexities, the predictions and conclu-
sions derived from the model regarding the expected
prevalence of MS in the general population are not
altered by the specific genetic configuration of each
locus.
In the case of a “dominant” allele at any particular
locus, the probability that a random individual in the
population will be in a “susceptible allelic state” (Pa1)a t
this location will be:
P2 a a h r a1 1 1
2 / = () − () =() (39)
Therefore, the expected allelic frequency, in this cir-
cumstance, will be [a1 =1− (1 − h/r)
1/2].
By contrast, in the case of a “recessive” allelic trait at
any particular locus, the probability that a random indi-
vidual in the population will be in a “susceptible allelic
state” (Pa2) at this location will be:
Pa h r a2 2
2 / =() =() (40)
Therefore, the expected allelic frequency, in this cir-
cumstance, will be [a2 = (h/r)
1/2].
For a “mixed dominance” allelic trait at a particular
locus, the probability that a random individual in the
population will be in a susceptible allelic state (Pa3)a t
this location will be:
Pa 2 1 2 a a2 a a a
2a a
a3 3
2
33 33 3
2
33
2
=() +− () ( ) + () () + ()
= () − () ⎡
⎣ ⎢
⎤ ⎤
⎦ ⎥+ () ⎡
⎣ ⎢
⎤
⎦ ⎥ == () / a2 a h r 3
2
3
(41)
and the apparent (mixed) allelic frequency is: [a3 =
(h/r)/2]. In the limit, as (r®∞), (a1 =a 3).
Estimating the Number of MS Susceptibility Loci
There are several epidemiological observations that are of
relevance to the possible genetic arrangements that might
produce MS susceptibility. First, as noted earlier, 45% of
MS patients in Canada do not carry the HLA DRB1*1501
allele and, therefore, do not have HLA DRB1*1501-asso-
ciated MS. Second, the proband-wise concordance rate
for the MS phenotype in identical-twin siblings (CRMZ)
in Canada is approximately 25% [11], which provides an
estimate of the average penetrance (Pt) of the MS pheno-
type (with a shared intra-uterine environment) for all
susceptibility genotypes. The penetrance of the HLA
DRB1*1501 genotype (Pt1) relative to the expected (i.e.,
average) penetrance of the other genotypes (Pt0)i sn o t
firmly established, although an estimate can be made
from the published data out of Canada [11] and, in this
dataset, Pt1 and Pt0 seem to be very similar (Table 3).
Third, the average concordance rate in Canada for non-
twin siblings of an MS proband is approximately 2.9%
[11]. By contrast, this same rate for dizygotic twins in
Canada is 5.4% [11], suggesting that the intrauterine
environment is important to MS pathogenesis [10]. As
discussed earlier, this requires that the expected pene-
trance for MS in non-twin siblings needs to be down-
weighted compared to the estimate taken from identical-
twin siblings (i.e., CR MZ(S) = Pt* = [Pt][2.9/5.4] = 0.134).
Fourth, the prevalence of MS in the general populations
of Canada is approximately 0.1-0.2% [2,11,16]. A similar
prevalence estimate pertains to northern European and
other North American populations [2,11-15].
Each of these epidemiological observations places con-
straints on the genetic possibilities. For example, based
only on the facts that 55% of MS patients have at least
one copy of the HLA DRB1*1501 allele and a proband-
wise identical-twin concordance rate of 25%, it is clear
that there must be susceptibility alleles at 3 or more dif-
ferent genetic loci and, moreover, that a “susceptible
allelic state” m u s tb ep r e s e n ta t2o rm o r e( b u tn o ta l l )
of these locations in order to produce susceptibility to
MS. Thus, if there were only one susceptibility locus (or
if there were two loci and both were necessary), then
every MS patient would be HLA DRB1*1501-positive
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ceptibility alleles at this location). Furthermore, if there
were two (or more) loci and a “susceptible allelic state”
at only one locus were necessary, then it would be diffi-
cult to explain a 25% penetrance for MS in identical-
twins in circumstances where only about 1 in 300 HLA
DRB1*1501-positive individuals in the general popula-
tion will ever develop MS and where only about 2.6% of
these individuals are even susceptible in the first place
(Additional File 1; Appendix S1; Section 4).
Further constraints are also imposed by these epide-
miological conditions. Thus, consider the circumstance
in which susceptibility to MS is conferred when an indi-
vidual has a “susceptible allelic state” at any 2 (or more)
of the (x + 1) susceptibility loci (haplotypes). For an
individual who is known to be susceptible to MS,
assuming independence of the haplotypes and using the
average “frequency of susceptibility” (F = h/r) at the
non-HLA DRB1 loci, the probability that this person
will be HLA DRB1*1501-negative can be calculated.
Thus, the probability of randomly picking the first of
these two loci (which must be in “susceptible allelic
states”) to be at a non-HLA DRB1 locus is:
xh r xh r h x x r // / / () () + () ⎡ ⎣ ⎤ ⎦=+ () ⎡ ⎣ ⎤ ⎦
The probability of picking the second locus also to be
a non-HLA DRB1 locus is:
x1 xr1 –/ – ()+ () ⎡ ⎣ ⎤ ⎦
The probability that the individual is also HLA
DRB1*1501-negative is (1−h = 0.76). Therefore, the
probability that all three of these conditions hold simul-
taneously is:
xx r x x r 1 7 6C // . + () ⎡ ⎣ ⎤ ⎦ ()+ () ⎡ ⎣ ⎤ ⎦[] = −1 − 0
where (C = 1 - hm) represents the actual proportion of
susceptible individuals who do not carry at least one
copy of the HLA DRB1*1501 allele. In the circumstance
where (Pt1 =P t 0), the observed proportion of HLA
DRB1*1501-negative MS patients (Cobs = 0.45) will be
equal to the true value of C (see Additional File 1;
Appendix S1; Section 2). In this case, then:
xx r x 1 x r 1  C * // + () ⎡ ⎣ ⎤ ⎦ () + () ⎡ ⎣ ⎤ ⎦ = −− (42)
where:
C* C 76 45 76 59 /. . /. . = () = () () = 00 0 0
In general (for n susceptibility loci) the probability of
being HLA DRB1*1501-negative is:
x r x x 1x r 1 x n 1x r n 1 C * // / + () ⎡ ⎣ ⎤ ⎦ () + () ⎡ ⎣ ⎤ ⎦ + () ++ () ⎡ ⎣ ⎤ ⎦ = −−− − 
or, equivalently:
xx1 xn1 xrxr1 xrn1 C * () ( ) + () ⎡ ⎣ ⎤ ⎦ + () +− () ++ () ⎡ ⎣ ⎤ ⎦= ––/ –  (43)
As shown in Additional File 1 (Appendix S1; Section
2), there is a relationship between the values that n, r,
and x can take in Equation (43). Thus, by solving the
different n-degree polynomials (in x)f o rv a r i o u sv a l u e s
of r, n,a n d( P t 1/Pt0), these relationships permit the cal-
culation of the number of non-HLA DRB1 susceptibility
loci that are required to support a specific number of
involved loci (i.e., that harbor susceptibility alleles) as
being necessary for MS to develop under specific
conditions.
For example, consider the circumstances, in which
(r =2 ) ,( n =4 )a n d( P t 1/Pt0 = 1). In this case, from
Equation (43), we get:
xx 2 x 1 x 1 x 2x x 3 x 1 /// / . + () ⎡ ⎣ ⎤ ⎦ − () + () ⎡ ⎣ ⎤ ⎦ − () ⎡ ⎣ ⎤ ⎦ − () − () ⎡ ⎣ ⎤ ⎦ =05 59
or:
x 5x 6 59 x 3x 2 so that 159
22 –. : . += + + () = 0 x
Thus, for this particular genetic configuration, there
must be 15 or 16 non-HLA DRB1 susceptibility loci
(haplotypes). The solutions to some of these equations
at specific values of (n), (r), and (Pt1/Pt0 =1 )a r ep r e -
sented in Tables 4 and 5.
Estimating the Concordance in a Non-twin Sibling (CRS)
There are also other constraints on the system. First, the
expected concordance for MS in non-twin siblings of an
MS proband is:
EC R E 1 C* PM S C* PM S 2 9 3 8 SH H () =− () ( ) +() ( ) ⎡ ⎣ ⎤ ⎦= +− .– . 00 00
where P(MSH+)a n dP ( M S H-) are the respective
probabilities that a non-twin sibling of an HLA
DRB1*1501-positive or HLA DRB1*1501-negative proband
is concordant for MS. Second, the average penetrance for
the different genotypes that confer MS susceptibility is
estimated by the proband-wise concordance rate for iden-
tical-twin siblings of an MS proband and (in northern
North America and northern Europe) is equal to:
Pt E 1 C Pt C Pt 25 1 . =− () +() ⎡ ⎣ ⎤ ⎦= 0 0 (44)
As discussed in Additional File 1 (Appendix S1; Sec-
tion 2), this implies that:
Pt 18 Pt   Pt 32  and  Pt 18 11 ≤ () ≤ () ≥ () ., . , . 00 00
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Page 13 of 28Table 4 (4a) The Estimated total number of non-HLA susceptibility genes (x) based on the number of such genes
necessary for MS to develop (n), and the frequency of susceptibility at the non-HLA susceptibility loci in the
population (Pt0 =P t 1)
Number of Susceptibility Genes Required (n)
5 1 0 1 11 21 31 41 5
Frequency of Susceptibility (r) Estimated Total Number of non-HLA Susceptibility Genes (x)
r = 0.25 5 11 12 13 14–15 15–16 16–17
r = 0.33 6 12 13–14 14–15 16 17–18 18–19
r = 0.5 7 14–15 16–17 17–19 19–20 21–22 22–23
r=1 1 1 –12 23–25 25–27 28–30 30–32 33–35 35–37
r=2 1 8 –22 40–44 45–48 49–53 53–57 58–61 62–66
r=4 3 5 –42 75–83 83–91 92–99 100–107 108–116 116–124
r=8 6 7 –82 146–161 162–177 177–193 193–208 209–224 225–240
r = 16 131–162 287–317 318–348 349–379 380–410 411–441 442–472
Frequency of Susceptibility (r) Estimated Prevalence (Target = 0.1–0.2%)
r = 0.25 11.5% 12.7% 12.7% 12.4% 12.3–13.2% 12.1–13.2% 12.0–13.1%
r = 0.33 7.5% 5.2% 4.4–6.7% 3.7–5.9% 5.1% 4.4–6.4% 3.8–5.7%
r = 0.5 3.5% 1.2–2.0% 1.4–2.1% 0.9–2.2% 1.1–1.6% 1.2–1.7% 0.8–1.2%
r = 1 1.8–2.4% 0.6–1.0% 0.4–0.7% 0.4–0.7% 0.28–0.48% 0.27–0.45% 0.19–0.33%
r = 2 1.1–2.0% 0.3–0.6% 0.28–0.43% 0.21–0.37% 0.16–0.28% 0.14–0.21% 0.10–0.18%
r = 4 1.0–1.9% 0.26–0.47% 0.20–0.36% 0.16–0.27% 0.12–0.21% 0.10–0.17% 0.07–0.13%
r = 8 1.0–1.8% 0.24–0.42% 0.18–0.32% 0.14–0.25% 0.11–0.19% 0.08–0.14% 0.06–0.11%
r = 16 0.9–1.7% 0.23–0.40% 0.17–0.30% 0.13–0.23% 0.09–0.18% 0.08–0.13% 0.06–0.10%
limit 1.27% 0.29% 0.22% 0.17% 0.13% 0.10% 0.07%
Optimal solutions underlined.
Table 5 (4b) The total number of non-HLA susceptibility genes (x) based on the number of such genes necessary for
MS to develop (n), and the frequency of susceptibility at the non-HLA susceptibility loci in the population (Pt0 =P t 1)
Total Number Susceptibility Genes Required (n)
16 17 18 30 40 50 60
Frequency of Susceptibility (r) Estimated Total Number of non-HLA Susceptibility Genes (x)
r = 0.25 18 19 20–21 33–35 44–46 56–58 67–71
r = 0.33 19–20 21 22–23 36–38 49–51 61–64 74–80
r = 0.5 24–25 25–26 27–28 44–47 60–62 75–78 91–101
r=1 37–39 40–42 42–44 71–75 95–100 120–124 144–166
r=2 66–70 71–74 75–79 125–133 168–176 212–220 255–300
r=4 124–132 132–140 140–148 234–250 316–331 397–413 478–569
r = 8 240–256 256–271 272–287 453–484 611–642 769–800 926–1109
r = 16 473–503 504–535 535–566 892–953 1202–1264 1512–1574 1823–2000
Frequency of Susceptibility (r) Estimated Prevalence (Target = 0.1–0.2%)
r = 0.25 13.1% 13.1% 13.0–13.3% 13.0–13.4% 13.1–13.4% 13.4% 13.4%
r = 0.33 3.2–5.0% 4.4% 3.8–5.6% 1.7–3.5% 1.6 –3.4% 1.0–3.1% 1.0–5.4%
r = 0.5 0.9–1.3% 0.6–1.0% 0.7–1.0% 0.10–0.35% 0.05–0.11% 0.01–0.05% 0.00–0.20%
r=1 0.14–0.24% 0.14–0.23% 0.10–0.17% 0.00–0.03% 0.00–0.00% 0.00–0.00% 0.00–0.00%
r=2 0.07–0.14% 0.07–0.10% 0.05–0.09% 0.00–0.00% 0.00–0.00% 0.00–0.00% 0.00–0.00%
r=4 0.06–0.10% 0.04–0.08% 0.03–0.06% 0.00–0.00% 0.00–0.00% 0.00–0.00% 0.00–0.00%
r = 8 0.05–0.09% 0.04–0.07% 0.03–0.05% 0.00–0.00% 0.00–0.00% 0.00–0.00% 0.00–0.00%
r = 16 0.05–0.08% 0.03–0.06% 0.03–0.05% 0.00–0.00% 0.00–0.00% 0.00–0.00% 0.00–0.00%
limit 0.06% 0.04% 0.03% 0.00% 0.00% 0.00% 0.00%
Goodin BMC Neurology 2010, 10:101
http://www.biomedcentral.com/1471-2377/10/101
Page 14 of 28However, these estimated penetrance values (Pt0 and
Pt1) include both the actual penetrance of the genotype
under normal circumstances plus the environmental
impact of sharing the same intrauterine environment.
As noted earlier [11], because the estimated fraternal
twin concordance rate (5.4%) is greater that the corre-
sponding rate for non-twin siblings (2.9%), the estimated
penetrance for an identical nuclear genome, outside of a
shared intrauterine environment, (Pt0*a n dP t 1*) needs
to be modified such that Equation (44) becomes:
** . . / . . Pt* E 1 C Pt C Pt 25 29 54 1 1 =− ()+() ⎡ ⎣ ⎤ ⎦=() ( ) = 0 00 0 0 00 3 34
Third, the prevalence of MS in the general population
is estimated to be:
PM S 1 2 () = .–.% 00
From these constraints, after assigning specific values
for (n, x, and r), P(MS) can be calculated as:
PM S P t 1 i 1 i h 1 h
1
i
i1 i
i
() = () () − () ( ) − ()
−
−
= ∑ ([ ( * ) ] [! /! ! ] [ ] ) *
[(
0
1
x xx j jP 1 P
x
11 a 1
j
a1
x1 j
j
ni
() − () ( ) ⎡ ⎣ ⎤ ⎦ ()− () ⎡
⎣ ⎢
⎤
⎦ ⎥
−
=
−−
∑ !/ ! ! )*
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0
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2 22 a 2
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nij
xkk P 1 P () − () ( ) ⎡ ⎣ ⎤ ⎦ ()− () ⎡
⎣ ⎢
⎤
⎦ ⎥
−
=
−−−
∑ !/ ! ! )*
(
0
1
!/ ! ! ))] xx m mP1 P 33 a 3
m
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x3 m
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nij
() − () () ⎡ ⎣ ⎤ ⎦ () − () ⎡
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⎦ ⎥
−
=
−−
0
− −−
∑
k1
If (n - i - 1 > x1), (n - i - j - 1 > x2), or (n - i - j - k - 1
>x 3), then all further entries of the summations invol-
ving (j > x1), (k > x2), or (m > x3) are set to [0].
Because binomial distributions [B(n, p)] have the
property that, if x1 and x2 are independent binary vari-
ables with distributions B(n1,p )a n dB ( n 2, p) respec-
tively, then (x1 +x 2) is also binomial with the
distribution B(n1 +n 2, p).
Thus, because, by the conditions of the model, (Pa1 =
Pa2 =P a3 = h/r), and letting (x = x1 +x 2 +x 3), this
equation can be rewritten as:
PM S P t 1 i 1 i h 1 h
1
i1 i
i
() = () () − () ( ) − ()
−
−
= ∑ ([ ( * ) ] [! /! ! ] [ ] ) *
[(
0
1
!/ ! ! / / )] xx j j h r 1 h r
jx j
j
ni
() − () ( ) ⎡ ⎣ ⎤ ⎦ () − () ⎡
⎣ ⎢
⎤
⎦ ⎥
−
−−
∑
1 (45)
In a similar manner, it is also possible to estimate the
concordance in non-twin siblings of an MS proband.
Thus, because the proband is known to have MS, one
or the other of the biological parents (taken together)
must possess at least the requisite number and combi-
nation of loci (haplotypes) that are in a “susceptible alle-
lic state” for MS to develop under proper environmental
circumstances. Assuming independence of the loci (hap-
lotypes), the probability that the other sibling will inherit
the “susceptible allelic state” at any specific locus from
the parent who has it can be calculated. For example,
the sibling of an HLA DRB1*1501-positive proband, has
a 50% chance of inheriting the HLA DRB1*1501 allele
from the parent who has it. This sibling also has a 50%
chance of receiving the other allele from this same par-
ent (which is of unknown status). This second allele has
the population probability of being HLA DRB1*1501
(i.e. ah = 0.128), so that the total probability of getting
an HLA DRB1*1501 allele from this parent is [0.5 +
(0.5)ah] or 56.4%. In addition their second allele (from
the other parent) at this locus (also of unknown status)
will have a 12.8% chance of being HLA DRB1*1501. The
sum of these probabilities (less the probability of being
homozygous for HLA DRB1*1501) will be the chance
that the second sibling will have at least one copy of the
HLA DRB1*1501 allele, given that the proband sibling is
HLA DRB1*1501-positive. Thus, this probability (PH) is:
P 5 1a a 5 1a  a
512 a
Hh h h h
h
.– .
.
=() + () +() ( ) + () ( )
=() +
00
0– –. % a6 2 h
2 () = 0
This is the same for all “dominant” true-susceptibility
alleles except that the non-HLA DRB1*1501 allelic fre-
quency ah r 1
12 11 =− − () ⎡
⎣ ⎢
⎤
⎦ ⎥ /
/ is substituted for (ah).
Thus, this probability (PA1) will be:
P5 1 2 a a A1 1 1
2 .– =[] + ⎡
⎣
⎤
⎦ 0
In the case of either a “recessive” true-susceptibility
alleles or an absent “dominant” protective allele, each
parent must possess at least one copy of the “suscept-
ibility” allele so that the probability (PA2)o fi n h e r i t i n g
two such alleles, based on the allelic frequency [a2 =
(h/r)
1/2], would be:
P 51a 2 51a A2 2
2
2
2 .. = () + () ⎡ ⎣ ⎤ ⎦ =[] + [] 00
In the case of “mixed dominance” alleles, the “known”
allelic state in the proband sibling could be either the
“dominant” or the “recessive” state so that the probabil-
ity (PA3) of inheriting this same state will be a mixture
of these two cases. Thus, the probability that the state
will be “recessive” is:
aa 2 a a a 2 3
2
3
2
33
2
3 () () + () ⎡
⎣
⎤
⎦
= () // −
and, therefore, the probability of the state being
“dominant” is [1-(a3)/2]. In the case this probability
(PA3) would be:
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Where the allelic frequency is [a3 = (h/r)/2].
Because the proband (affected) sibling is only required
to be in a “susceptible allelic state” at (n) of the (x +1 )
susceptibility loci, the allelic status at the other (x +1
−n) loci is not constrained by having an affected sibling
and, therefore, the probability that these other loci are
in a “susceptible state” will reflect their population “fre-
quency of susceptibility”. By contrast, if the proband is
HLA DRB1*1501-negative, because it is known that 2 of
the 4 parental alleles can not be HLA DRB1*1501, the
probability that a sibling (not an identical-twin) is HLA
DRB*1501-positive (Ph1) will be about once (not twice)
the population allelic frequency. Thus:
P5 a 5 a 5 a
a 25 a
h1 h h h
2
hh
2
.. – .
–.
=() ( ) + () ( )() ( ) ⎡ ⎣ ⎤ ⎦
= () ⎡
⎣
00 0
0 ⎢ ⎢
⎤
⎦ ⎥
Using (PH), (PA1), (PA2), and (PA3) for alleles necessa-
rily present in the parents (described above) and using
(Ph1), (Pa1), (Pa2), and (Pa3) for alleles not necessarily
present, the equation for the probability of concordance
in a non-twin sibling of an HLA DRB1*1501-positive
proband can be calculated.
Thus, setting (Pa1 =P a2 =P a3 =h / r )a n d( x=x 1 +x 2
+x 3) and letting n1,n 2 and n3 be the respective number
of dominant, recessive and mixed dominant loci among
the loci necessarily present in the parents, this expres-
sion is:
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(46)
If (n - i -1 > n1), (n - i - j -1 > n2), (n - i - j - k -1 >
n3), or (n - i - j - k - m -1 > x), then all further entries
of the summations involving (j > n1), (k > n2), (m > n3),
or (p > x) are set equal to [0]. NB: In this circumstance
(n1 +n 2 +n 3 = n - 1).
For a non-twin sibling of an HLA DRB1*1501-negative
proband, this becomes:
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If (n - i -1 > n1), (n - i - j -1 > n2) ,( n-i-j-k- 1>
n3), or, (n - i - j - k - m -1 > x), then all further entries
of the summations involving (j > n1), (k > n2), (m > n3),
or (p > x) are set equal to [0]. NB: In this circumstance
(n1 +n 2 +n 3 = n).
As noted earlier, the expected concordance rate would
then be the weighted average of these two rates (based
on the population prevalence HLA DRB1*1501-positive
probands) or:
E C R 1 CP M S CP M S SH H () =− () ( ) +() ( ) +− **
Estimating Concordance in Other Relatives
The observed recurrence risks in parents and children
(CRPC), in aunts and uncles (CRAU), and in first cousins
(CRFC) place further constraints on the system (5, 6). To
predict these risks, however, requires that Equations
(46) and (47) to be modified to include modified esti-
mates for (PA1,P A2,P A3,P H,a n dP h1). In the case of a
dominant allele, for either the biological parent or the
child of an MS proband (first degree relatives with 50%
genetic sharing), these expressions would be the same as
those for a sibling. For the recessive case, however, both
parent and child necessarily possess one susceptibility
allele, so that their chance of being concordant for MS
is:
P5 a 5 a a A2 2 2 2 .. =() ( ) +() ( ) = 00
In the case of an Aunt or Uncle (second degree rela-
tives with 25% genetic sharing), however, the dominant
and recessive formulas become:
P2 5 1 6 a 3 a
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Goodin BMC Neurology 2010, 10:101
http://www.biomedcentral.com/1471-2377/10/101
Page 16 of 28Whereas for First Cousins (third degree relatives with
12.5% genetic sharing), they become:
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For a child of two parents who each have MS, the
probability of either parent having being susceptible at
any specific susceptibility locus is (n/x) so that the prob-
ability of both parents being in a “susceptible allelic
state” at any particular locus is (n/x)
2. In this case,
therefore:
P1 n x 5 1 2 aa
nx 7 5
A1
2
11
2
2
–/ . –
/..
= () ⎡
⎣ ⎢
⎤
⎦ ⎥() + () ⎡
⎣ ⎢
⎤
⎦ ⎥
+() +
0
00 5 5a 2 5 a
P1 n x 2 5 1 a
11
2
A2
2
2
2
() ( ) ( ) ⎡
⎣ ⎢
⎤
⎦ ⎥
= () ⎡
⎣ ⎢
⎤
⎦ ⎥() + []
–.
–/ .
0
0 + +() ( )
= () ⎡ ⎣ ⎤ ⎦[] + () ⎡ ⎣ ⎤ ⎦[]
/
–/ /
nx 1
P1 a 2 P a 2 P
2
A3 3 A1 3 A1
And (if one parent was known to carry the HLA
DRB1*1501 allele):
P5 1 2 a a Hh h
2 = () ++ () ⎡
⎣ ⎢
⎤
⎦ ⎥ 0.
And if neither parent carries this allele:
P a 25 a h1 h h
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For a recessive allele and both parents affected, the
relationship is:
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Computational Methods
A computer program was written in using the visual
basic language on an Excel® (Microsoft Corp.) platform
in order to calculate the expected prevalence of MS in
the general population and the expected recurrence
rates for MS in 1
st,2
nd,a n d3
rd degree relatives of an
MS proband at different parameter values of (n) and (r).
This program substituted the different combinations of
(r = 0.25, 0.33, 0.5, 1, 2, 4, 8, and 16), (n = 5 to 60), and
(x = 4 to 2000) into Equation (43) in a systematic
fashion and then, for each combination of (r)a n d( n),
determined the values of (x) that provided a solution to
Equation (43) that fell within the range of:
C* 5 ± () 00 ..
The output of this process gave a range of possible
values for (x) at each combination of (r)a n d( n). The
high and low ends of this range were taken as the high
and low estimates of (x) for the specific combination.
These values of (x)w e r et h e nu s e di ns o l v i n gE q u a t i o n
(44) to estimate the prevalence of MS. To calculate the
recurrence risks in 1
st,2
nd,a n d3
rd degree relatives of
M Sp r o b a n d s ,t h ev a l u e so f( h ,P h1,P H,P a1,P A1,p a2,
PA2,P a3,a n dP A3) were substituted into Equations (46)
and (47) as discussed above, using the values of (x)
derived from the first step in the process. This program
was spot-checked by hand for accuracy of the calculated
probability at several different combinations of para-
meter values for (n, x,a n dr). In addition it was vali-
dated substituting identical probabilities for (h, h/r, Ph1,
PH,P a1,P A1,p a2,P A2,P a3,a n dP A3) and comparing the
calculations output by the program to the actual bino-
mial distribution for numerous combinations of (n1, n2,
n3, and x). This remarked visual basic program is avail-
able upon request.
The “Closeness of Fit” (CoF) measure was calculated
as the squared percent deviations from published epide-
miological (E) data [2,5,6,16] of the calculated the high
(H) and low (L) estimates (from the model equations)
for the prevalence of MS in the general population and
for the concordance rates of MS (from the model equa-
tions) in non-twin siblings, parents/children, offspring of
conjugal MS couples, and second and third degree rela-
tives (see Table 12). Thus, the equation for this measure
was:
CoF H E E L E E
2
=− () +− () ⎡ ⎣ ⎤ ⎦ //
These five squared deviations were then summed and
the minimum value of the sum determined for the
entire matrix extending from (r = 0.25 to 16) and from
(n = 5 to 60). This metric is similar to a chi square
calculation for the average deviation of the high and
low model predictions from the published epidemiolo-
gical data for each unique combination of values for
(x), (n), and (r). Because each combination was used to
generate the entire set of estimates, there was only a
single degree of freedom for each set. A chi-square dis-
tribution with 1 degree of freedom has a critical value
of 3.84. Therefore, any set of estimates with a close-
ness of fit less the 4 was considered to be reasonably
close.
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Tables 4 and 5 show the total number of non-HLA DRB1
genes required (x) for different parameter values of (n)
and (r) as well as the estimated disease prevalence at
these different combinations. Tables 6, 7, 8, 9, 10, and 11
show the predicted concordance rates for first, second,
and third degree relatives of MS probands under the
same conditions. These tables are also re-presented for
illustrative purposes (with color highlighting for clarity)
in the Appendix S1 (see Additional File 1; Section 6). For
example, in the case where (r =1 ) ,( n =5 ) ,a n d( P t 1*=
Pt0* = 0.134), there must be a total of (x +1 = 12-13) sus-
ceptibility genes, as indicated in Table 5. Also, from
Tables 4, 5, 6, 7, 8, and 9, substituting these values into
the appropriate equations yield the estimates of:
EC R 6 4 8 2
EPM S 1 8 2 4  
S ()=
() {} =
.. %
.. %
−
−
Neither of these is in line with epidemiological obser-
vations. Both the predicted MS concordance in siblings
and the predicted disease prevalence from this specific
genetic arrangement greatly exceed the observed rates
[2,5,6,11,20]. Moreover, as also indicated in the Table 4,
regardless of the value assigned to (r), when (n = 5), the
predicted value of P(MS) can never be less than 1.27%
(see Additional File 1; Appendix S1; Section 2), which is
far too high. Consequently, there must be more than
five loci in a susceptible state in order to produce MS
susceptibility in an individual.
In fact, perusal of Tables 4, 5, 6, 7, 8, 9, 10, 11, and
12, leads to several other conclusions. First, in the cir-
cumstances where (Pt1 =P t 0)i ts e e m st h a ta p p r o x i -
mately 18 loci represents an upper bound for the
average number of loci needed to be in a susceptible
state in order to produce susceptibility to MS. Any
more than this and the predicted prevalence will be too
low. There are (and will continue to be) solutions at
higher values of (n), which, as discussed in Additional
File 1 (Appendix S1; Section 3), will be increasingly con-
centrated near the limiting value of (r = 0.53). Neverthe-
less, these solutions are probably spurious as suggested
by the Closeness of Fit estimates considering all rela-
tives, which, as shown in Table 13, are best for the solu-
tion space in which (11 ≤ n ≤ 18) and (r ≥ 2).
Moreover, it seems the frequency with which these non-
HLA DRB1 loci are in a susceptible state in the general
population are less than the frequency of susceptibility
at the HLA DRB1 locus because, otherwise, the pre-
dicted concordance is too high. The range for the total
number of non-HLA DRB1 loci is 35 to 472, although
most of the solutions are between 50 and 200 (Tables 4,
Table 6 (5a) Predicted concordance rates of MS in siblings of MS probands assuming (Pt0 =P t 1) and either 100%
Dominant genes or 100% Recessive genes
Number of Susceptibility Genes Required (n)
51 01 11 2 1 3 1 4 1 5
Frequency of Susceptibility (r) Predicted Concordance in Non-twin Siblings (100% of Genes Dominant)
r = 0.25 12.6% 13.2% 13.2% 13.2% 13.1–13.4% 13.1–13.4% 13.0–13.4%
r = 0.33 10.9% 10.7% 9.8–11.4% 10.2% 10.7% 10.3–11.6% 9.9–11.3%
r = 0.5 8.5% 7.9–9.1% 7.7–8.9% 6.9–9.3% 7.5–8.6% 8.0–9.0% 7.3–8.4%
r = 1 7.4–8.2% 6.4–7.6% 6.3–7.4% 6.6–7.6% 6.3–7.3% 6.5–7.5% 6.2–7.2%
r = 2 6.6–8.0% 6.4–7.5% 6.4–7.1% 6.2–7.2% 6.1–7.0% 6.2–6.8% 6.0–6.9%
r = 4 6.7–7.9% 6.3–7.3% 6.1–7.1% 6.2–7.0% 6.1–6.9% 6.0–6.9% 6.0–6.8%
r = 8 6.6–7.9% 6.3–7.2% 6.2–7.1% 6.1–7.0% 6.0–6.9% 6.0–6.8% 6.0–6.7%
r = 16 6.6–7.9% 6.3–7.2% 6.1–7.0% 6.1–6.9% 6.0–6.8% 6.0–6.8% 5.9–6.7%
Frequency of Susceptibility (r) Predicted Concordance in Non-twin Siblings (100% of Genes Recessive)
r = 0.25 12.6% 13.2% 13.2% 13.1% 13.1– 13.4% 13.1–13.4% 13.2–13.4%
r = 0.33 10.8% 10.1% 9.6–11.3% 9.1–10.9% 10.5% 10.1–11.5% 9.7–11.2%
r = 0.5 8.1% 6.4–7.8% 7.0–8.2% 6.2–8.6% 6.7–7.9% 7.2–8.3% 6.5–7.6%
r = 1 6.4–7.2% 5.2–6.3% 4.8–5.9% 5.0–6.0% 4.6–5.6% 4.8–5.7% 4.5–5.4%
r = 2 5.0–6.5% 4.1–5.1% 4.1–4.8% 3.9–4.8% 3.7–4.5% 3.7–4.3% 3.5–4.3%
r = 4 4.8–6.0% 3.5–4.4% 3.3–4.2% 3.3–4.0% 3.1–3.8% 3.0–3.7% 2.8–3.5%
r = 8 4.3–5.7% 3.1–4.0% 3.0–3.7% 2.8–3.5% 2.6–3.3% 2.5–3.1% 2.4–3.0%
r = 16 4.0–5.4% 2.8–3.6% 2.7 –3.4% 2.5–3.2% 2.3–3.0% 2.2–2.8% 2.1–2.6%
(Target = 2.9–3.8% is in bold; optimal solution underlined).
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Page 18 of 28Table 7 (5b) Predicted concordance rates of MS in siblings of MS probands assuming (Pt0 =P t 1) and either 100%
Dominant genes or 100% Recessive genes
Number of Susceptibility Genes Required (n)
16 17 18 30 40 50 60
Frequency of Susceptibility (r) Predicted Concordance in Non-twin Siblings (100% of Genes Dominant)
r = 0.25 13.4% 13.4% 13.3 - 13.4% 13.4% 13.4% 13.4% 13.4%
r = 0.33 9.5 - 11.0% 10.7% 10.4 - 11.6% 9.4 - 11.6% 10.4 - 12.0% 10.2 - 12.3% 10.9 - 13.2%
r = 0.5 7.8 - 8.8% 7.2 - 8.2% 7.7 - 8.6% 6.2 - 8.6% 6.7 - 8.1% 6.4 - 8.3% 6.8 - 11.4%
r = 1 6.0 - 6.9% 6.2 - 7.1% 6.0 - 6.8% 5.5 - 6.8% 5.1 - 6.5% 5.1 - 6.1% 4.8 - 9.6%
r = 2 6.0 - 6.8% 6.0 - 6.6% 5.9 - 6.7% 5.2 - 6.4% 4.9 - 6.0% 4.8 - 5.7% 4.6 - 9.2%
r = 4 5.9 - 6.7% 5.8 - 6.6% 5.8 - 6.5% 5.1 - 6.3% 5.0 - 5.9% 4.8 - 5.6% 4.6 - 9.0%
r = 8 5.9 - 6.7% 5.9 - 6.6% 5.8 - 6.5% 5.1 - 6.2% 4.9 - 5.9% 4.8 - 5.6% 4.6 - 9.0%
r = 16 5.9 - 6.6% 5.8 - 6.6% 5.8 - 6.5% 5.2 - 6.2% 5.0 - 5.9% 4.8 - 5.6% 4.6 - 6.8%
Frequency of Susceptibility (r) Predicted Concordance in Non-twin Siblings (100% of Genes Recessive)
r = 0.25 13.4% 13.4% 13.3 - 13.4% 13.4% 13.4% 13.4% 13.4%
r = 0.33 9.2 - 10.8% 10.5% 10.1 - 11.4% 9.1 - 11.4% 10.5 - 11.8% 9.8 - 12.1% 10.5 - 13.1%
r = 0.5 7.0 - 8.0% 6.3 - 7.4% 6.8 - 7.8% 5.1 - 7.5% 5.2 - 6.7% 4.9 - 6.8% 5.1 - 10.3%
r = 1 4.2 - 5.0% 4.3 - 5.2% 4.1 - 4.9% 3.2 - 4.3% 2.6 - 3.7% 2.3 - 3.1% 1.9 - 6.2%
r=2 3.3 - 4.1% 3.3 - 3.9% 3.2 - 3.9% 2.1 - 2.9% 1.6 - 2.2% 1.3 - 1.7% 1.0 - 4.0%
r=4 2.7 - 3.3% 2.6 - 3.2% 2.5 - 3.0% 1.4 - 2.1% 1.0 - 1.5% 0.7 - 1.1% 0.5 - 2.7%
r = 8 2.3 - 2.8% 2.2 - 2.7% 2.1 - 2.5% 1.1 - 1.6% 0.7 - 1.0% 0.5 - 0.7% 0.3 - 1.9%
r = 16 2.0 - 2.5% 1.9 - 2.3% 1.8 - 2.2% 0.8 - 1.3% 0.5 - 0.8% 0.3 - 0.5% 0.2 - 0.6%
(Target = 2.9 - 3.8% is in bold).
Table 8 (6a) Predicted concordance rates of MS in first degree relatives of MS probands assuming (Pt0 =P t 1), 20%
Dominant genes and 80% Recessive genes
Number of Susceptibility Genes Required (n)
51 01 11 2 1 3 1 4 1 5
Frequency of Susceptibility (r) Predicted Concordance in Non-twin Siblings (Target = 2.9 - 3.8%)
r = 0.25 12.6% 13.2% 13.2% 13.1% 13.1 - 13.4% 13.1 - 13.4% 13.0 - 13.4%
r = 0.33 10.8% 10.1% 9.6 - 11.3% 9.1 - 10.9% 10.5% 10.1 - 11.5% 9.7 - 11.2%
r = 0.5 8.1% 6.5 - 7.9% 7.1 - 8.3% 6.3 - 8.7% 6.8 - 8.0% 7.3 - 8.4% 6.6 - 7.8%
r = 1 6.5 - 7.3% 5.4 - 6.6% 5.1 - 6.2% 5.2 - 6.3% 4.9 - 5.9% 5.0 - 6.0% 4.8 - 5.7%
r = 2 5.2 - 6.7% 4.4 - 5.4% 4.5 - 5.2% 4.3 - 5.2% 4.0 - 4.9% 4.0 - 4.6% 3.9 - 4.7%
r = 4 5.0 - 6.2% 3.9 - 4.8% 3.8 - 4.7% 3.7 - 4.5% 3.5 - 4.2% 3.4 - 4.1% 3.3 - 4.0%
r = 8 4.6 - 5.9% 3.5 - 4.4% 3.5 - 4.3% 3.3 - 4.0% 3.1 - 3.8% 2.9 - 3.6% 2.9 - 3.5%
r = 16 4.3 - 5.6% 3.3 - 4.1% 3.2 - 4.0% 3.0 - 3.7% 2.8 - 3.5% 2.6 - 3.3% 2.6 - 3.2%
Frequency of Susceptibility (r) Predicted Concordance in Parents/Children (Target = 1.8 - 2.1%)
r = 0.25 12.6% 13.2% 13.2% 13.1% 13.1 - 13.4% 13.1 - 13.4% 13.0 - 13.4%
r = 0.33 10.7% 9.9% 9.4 - 11.2% 8.9 - 10.8% 10.4% 9.9 - 11.4% 9.5 - 11.0%
r = 0.5 7.7% 5.9 - 7.3% 6.5 - 7.8% 5.7 - 8.2% 6.2 - 7.4% 6.6 - 7.8% 6.0 - 7.1%
r = 1 5.6 - 6.4% 4.3 - 5.4% 3.9 - 5.0% 4.0 - 5.0% 3.6 - 4.5% 3.7 - 4.6% 3.4 - 4.3%
r = 2 3.7 - 5.3% 2.8 - 3.7% 2.9 - 3.6% 2.6 - 3.4% 2.4 - 3.1% 2.3 - 2.8% 2.2 - 2.8%
r = 4 3.3 - 4.5% 2.1 - 2.8% 2.0 - 2.7% 1.8 - 2.4% 1.6 - 2.1% 1.5 - 2.0% 1.4 - 1.9%
r = 8 2.7 - 3.9% 1.6 - 2.2% 1.5 - 2.1% 1.3 - 1.8% 1.1 - 1.6% 1.0 - 1.4% 1.0 - 1.3%
r = 16 2.3 - 3.5% 1.2 - 1.7% 1.2 - 1.7% 1.0 - 1.4% 0.8 - 1.2% 0.7 - 1.0% 0.7 - 0.9%
(Targets are in bold; optimal solution underlined)
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Page 19 of 28Table 9 (6b) Predicted concordance rates of MS in first degree relatives of MS probands assuming (Pt0 =P t 1),
20% Dominant genes and 80% Recessive genes
Number of Susceptibility Genes Required (n)
16 17 18 30 40 50 60
Frequency of Susceptibility (r) Predicted Concordance in Non-twin Siblings (Target = 2.9–3.8%)
r = 0.25 13.4% 13.4% 13.3–13.4% 13.4% 13.4% 13.4% 13.4%
r = 0.33 9.3–10.9% 10.5% 10.2–11.4% 9.9–11.0% 10.1–11.9% 9.9–12.1% 10.6–13.1%
r = 0.5 7.1–8.2% 6.5–7.5% 6.9–7.9% 5.3–7.7% 5.6–7.0% 5.2–7.1% 5.5–10.5%
r = 1 4.5–5.4% 4.6–5.5% 4.4–5.2% 3.5–4.7% 3.0–4.2% 2.8–3.6% 2.4–6.9%
r = 2 3.8–4.5% 3.8–4.3% 3.6–4.3% 2.5–3.5% 2.0–2.7% 1.7–2.3% 1.4–4.9%
r=4 3.2–3.9% 3.1–3.7% 2.9–3.6% 1.9–2.7% 1.5–2.0% 1.2–1.6% 0.9–3.7%
r=8 2.8–3.5% 2.7–3.3% 2.6–3.1% 1.5–2.2% 1.1–1.6% 0.8–1.2% 0.6–2.9%
r=1 6 2.5–3.1% 2.4–2.9% 2.3–2.8% 1.3–1.9% 0.9–1.3% 0.6–0.9% 0.5–1.1%
Frequency of Susceptibility (r) Predicted Concordance in Parents/Children (Target = 1.8–2.1%)
r = 0.25 13.4% 13.4% 13.3–13.4% 13.4% 13.4% 13.4% 13.4%
r = 0.33 9.1–10.7% 10.4% 10.0–11.3% 8.8–11.2% 9.3–11.3% 9.6–11.9% 10.3–13.0%
r = 0.5 6.4–7.5% 5.8–6.8% 6.2–7.2% 4.4–6.7% 4.6–5.9% 4.1–5.9% 4.2–9.5%
r = 1 3.2–4.0% 3.3–4.0% 3.0–3.7% 2.0–3.0% 1.5–2.3% 1.2–1.7% 0.9–4.1%
r=2 2.1–2.9% 2.0–2.4% 1.8–2.4% 0.9–1.4% 0.6–0.9% 0.4–0.6% 0.2–1.7%
r=4 1.4–1.8% 1.2–1.6% 1.1–1.5% 0.4–0.7% 0.2–0.4% 0.1–0.2% 0.1–0.7%
r = 8 0.9–1.3% 0.8–1.1% 0.7–1.0% 0.2–0.4% 0.1–0.2% 0.0–0.1% 0.0–0.3%
r = 16 0.7–0.9% 0.6–0.8% 0.5–0.7% 0.1–0.2% 0.0–0.1% 0.0% 0.0%
(Targets are in bold)
Table 10 (7a) Predicted concordance rates of MS in second and third degree relatives of MS probands assuming
(Pt0 =P t 1), 20% Dominant genes and 80% Recessive genes
Number of Susceptibility Genes Required (n)
51 01 11 2 1 3 1 4 1 5
Frequency of Susceptibility (r) Predicted Concordance in Second Degree Relatives (Target = 0.9–1.6%)
r = 0.25 12.1% 13.0% 12.9% 12.8% 12.8–13.3% 12.7-13.3% 12.6–13.3%
r = 0.33 9.2% 7.6% 6.8–9.1% 6.1–8.4% 7.8% 7.1–9.1% 6.5–8.5%
r = 0.5 5.6% 3.2–4.4% 3.5–4.7% 2.8–5.0% 3.1–4.1% 3.4–4.4% 2.7–3.7%
r = 1 3.7–4.5% 2.1–2.9% 1.8–2.5% 1.8–2.4% 1.5–2.1% 1.5–2.0% 1.3–1.8%
r = 2 2.5–3.9% 1.4–2.0% 1.4–1.8% 1.2–1.7% 1.0–1.4% 0.9–1.2% 0.8–1.2%
r = 4 2.4–3.5% 1.1–1.7% 1.0–1.5% 0.9–1.3% 0.8–1.1% 0.7–1.0% 0.6–0.9%
r = 8 2.1–3.2% 1.0–1.4% 0.9–1.3% 0.7–1.1% 0.6–0.9% 0.5–0.8% 0.5–0.7%
r = 16 1.9–3.0% 0.9–1.3% 0.8–1.1% 0.6–0.9% 0.5–0.8% 0.5–0.7% 0.4–0.6%
Frequency of Susceptibility (r) Predicted Concordance in Third Degree Relatives (Target = 0.9%)
r = 0.25 11.8% 12.9% 12.8% 12.7% 12.5–13.3% 12.4–13.2% 12.3–13.2%
r = 0.33 8.3% 6.3% 5.5–7.9% 4.8–7.1% 6.4% 5.7–7.8% 5.0–7.1%
r = 0.5 4.4% 2.0–3.0% 2.3–3.3% 1.7–3.4% 1.9–2.7% 2.1–2.9% 1.6–2.2%
r = 1 2.7–3.3% 1.1–1.7% 0.9–1.4% 0.9–1.3% 0.7–1.1% 0.7–1.0% 0.5–0.8%
r = 2 1.7–2.8% 0.7–1.1% 0.6–0.9% 0.5–0.8% 0.4–0.7% 0.4–0.5% 0.3–0.5%
r = 4 1.6–2.5% 0.5–0.9% 0.5–0.7% 0.4–0.6% 0.3–0.5% 0.3–0.4% 0.2–0.3%
r = 8 1.4–2.4% 0.5–0.8% 0.4–0.6% 0.3–0.5% 0.3–0.4% 0.2–0.3% 0.2–0.3%
r = 16 1.3–2.2% 0.4–0.7% 0.3–0.5% 0.3–0.5% 0.2–0.4% 0.2–0.3% 0.1–0.2%
(Targets are in bold; optimal solution is underlined)
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Page 20 of 28and 5). Indeed, the optimal solution occurs when 80% of
the loci are recessive and at (x = 100-107; n = 13; and
r = 4).
Naturally, the situation changes when the penetrance
ratio (Pt1/Pt0) is altered. In general, as (Pt1)i n c r e a s e s
(and as C* approaches its limit of 0.79), the number of
necessary loci (n) increases. For example, at the value of
(Pt1 = 0.27), the point of optimal fit occurs at (n =1 9 )
and (r = 16) with a Closeness of Fit estimate of (3.36). If
all the alleles are recessive, the optimal fit occurs at (n =
22) and (r = 4) with a Closeness of Fit of (3.25). In this
last circumstance, the solution space is the solution
space in which (18 ≤ n ≤ 26) and (r ≥ 4). After the limit
of (C* = 0.79) is reached, for any increase in this ratio,
Table 11 (7b) Predicted concordance rates of MS in second and third degree relatives of MS probands assuming (Pt0 =
Pt1), 20% Dominant genes and 80% Recessive genes
Number of Susceptibility Genes Required (n)
16 17 18 30 40 50 60
Frequency of Susceptibility (r) Predicted Concordance in Second Degree Relatives (Target = 0.9 - 1.6%)
r = 0.25 13.3% 13.2% 13.2 - 13.4% 13.2 - 13.4% 13.3 - 13.4% 13.4% 13.4%
r = 0.33 5.9 - 8.0% 7.4% 6.8 - 8.6% 4.6 - 7.6% 5.0 - 7.7% 4.3 - 7.8% 4.6 - 10.5%
r = 0.5 3.0 - 3.9% 2.4 - 3.3% 2.7 - 3.5% 1.1 - 2.3% 0.9 - 1.4% 0.5 - 1.1% 0.4 - 3.0%
r=1 1.1 - 1.5% 1.1 - 1.5% 0.9 - 1.3% 0.3 - 0.6% 0.1 - 0.3% 0.1% 0.0 - 0.1%
r=2 0.7 - 1.0% 0.7 - 0.9% 0.6 - 0.8% 0.1 - 0.3% 0.1% 0.0% 0.0%
r = 4 0.5 - 0.8% 0.5 - 0.7% 0.4 - 0.6% 0.1 - 0.2% 0.0 - 0.1% 0.0% 0.0%
r = 8 0.4 - 0.6% 0.4 - 0.5% 0.3 - 0.5% 0.1% 0.0% 0.0% 0.0%
r = 16 0.4 - 0.5% 0.3 - 0.5% 0.3 - 0.4% 0.0 - 0.1% 0.0% 0.0% 0.0%
Frequency of Susceptibility (r) Predicted Concordance in Third Degree Relatives (Target = 0.9%)
r = 0.25 13.2% 13.1% 13.1 - 13.4% 13.1 - 13.4% 13.2 - 13.4% 13.4% 13.4%
r = 0.33 4.5 - 6.4% 5.8% 5.2 - 7.1% 2.9 - 5.6% 3.1 - 5.4% 2.2 - 5.2% 2.4 - 8.0%
r = 0.5 1.7 - 2.4% 1.3 - 1.9% 1.4 - 2.0% 0.4 - 1.0% 0.2 - 0.4% 0.1 - 0.2% 0.1 - 1.0%
r = 1 0.4 - 0.7% 0.4 - 0.6% 0.3 - 0.5% 0.1% 0.0% 0.0% 0.0%
r = 2 0.3 - 0.4% 0.2 - 0.3% 0.2 - 0.3% 0.0 - 0.1% 0.0% 0.0% 0.0%
r = 4 0.2 - 0.3% 0.1 - 0.2% 0.1 - 0.2% 0.0% 0.0% 0.0% 0.0%
r = 8 0.1 - 0.2% 0.1 - 0.2% 0.1 - 0.2% 0.0% 0.0% 0.0% 0.0%
r = 16 0.1 - 0.2% 0.1 - 0.2% 0.1% 0.0% 0.0% 0.0% 0.0%
(Targets are in bold)
Table 12 (8) Observed and the optimal predicted concordance rates and prevalence rates for MS under different
conditions
Observed (Estimated)* 100% Recessive 80% Recessive 100% Dominant 100% Mixed
Number Genes Needed (n) - 14 13 58 58
Frequency of Susceptibility (r)- 2 4 2 2
Total Non-HLA Genes (x) - 58 - 61 100 - 107 246-254 246 - 254
Relationship
Prevalence [2,19] 0.1 - 0.2% (1.5) 0.14 - 0.21% 0.12 - 0.21% 0.00% 0.00%
Non-twin Sibling [5,6] 2.9 - 3.8% (3.0) 3.7 - 4.3% 3.3 - 4.1%. 4.6 - 5.4% 4.5 - 5.3%
Offspring, Conjugal MS** ~10% (10.0) 11.9 - 12.1% 10.3 - 10.8% 13.4% 13.2 - 13.3%
Parent/Child [5] 1.8 - 2.1% (2.0) 1.8 - 2.3% 1.3 - 1.8% 4.6 - 5.4% 4.3 - 5.1%
Second Degree [5] 0.9 - 1.6% (1.0) 0.8 - 1.1% 0.7 - 1.1% 0.1% 0.1%
Third Degree [5] 0.9% (0.9) 0.3 - 0.5% 0.3 - 0.5% 0.00% 0.00%
Closeness of Fit - 1.8 1.7 22.7 20.6
* The estimates (Targets) used to calculate closeness of fit are shown in parentheses. Closeness of fit was measured as the sum of the squared percent deviations
of both the high and the low prediction from the Target. The optimal estimate was taken as the estimate at the values of x, n, and r that gave the closest fit to
the observations.
** The concordance rate for the offspring of Conjugal MS is based on the report of Sadovnick et al. [6], in which the recurrence rate in offspring of two parents
with MS is reported to be 78% of the monozygotic twin rate (CRMZ).
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decreases) so that it can never approach the observed
values for concordance and prevalence (see Additional
File 1; Appendix S1; Section 3). Similarly, the number of
necessary loci (n) also increases either as (h) is increased
above the observed value of (h = 0.24) or as (hm)i s
decreased below the observed value of (hm =0 . 5 5 ) .B y
contrast, (n) decreases as either (h) is decreased or (hm)
is increased. The Closeness of Fit estimates under these
conditions, however, is generally worse.
As shown in Table 14, when the odds ratio for the
HLA DRB1*1501 allele is adjusted to equal its
observed value of (OR = 3.3) for conditions (h = 0.24;
hm = 0.55), the expected odds ratios for recessive non-
HLA DRB1 loci (when Pt0 =P t 1) is approximately
(OR ≈ 1.6 - 1.7). By contrast, the expected odds ratio
for dominant non-HLA DRB1 loci is (OR ≈ 2.2) under
these same conditions (Table 15). These odds ratios
are altered both as (Pt1), (h), or (hm) are changed from
their observed values and also when more than one
susceptibility allele is assumed to be present at a locus
(see Additional File 1; Appendix S1). For example, at
the value of (Pt1 = 0.27) and with 2 susceptibility
alleles at each non-HLA DRB1 locus but with (h) and
(hm) unchanged, the expected odds ratio for recessive
alleles at loci, in which heterozygotes having two dif-
ferent recessive alleles still confers susceptibility, is
(OR = 1.3 - 1.4), whereas, for dominant alleles, it is
(OR = 1.7 - 1.9).
Second, as shown in Table 5 and 6, there are no
appropriate solutions when all of the loci are assumed
to be “dominant”. Thus, the smallest recurrence rate in
the case of 100% “dominant” loci (and with Pt0 =P t 1)i s
greater than 4.6% and the Closeness of Fit estimate is
poor (Table 13). If (Pt0 <P t 1), this calculated recurrence
rate only increases. The same is true for mixed domi-
nance loci (Table 13). In fact, only when a small fraction
of the loci are assumed to be “dominant” does the close-
ness of fit become good. Similarly, mixed dominance
loci also provide poor solutions (Table 13), presumably
because they effectively function as “dominant” loci at
low allelic frequencies. Moreover, it is of note that all of
these calculations have been made on the “adjusted”
estimates of penetrance (Pt*; see Table 3) based on the
observation that dizygotic twins (with their shared
intrauterine environment) seem to have a greater pene-
trance of MS compared to non-twin siblings [11]. If the
same calculations were made using an unadjusted esti-
mate of penetrance (Pt), these calculated recurrence
rates would be almost twice as high and the Closeness
of Fit estimate substantially worse compared to the use
of adjusted penetrance estimates.
It seems that the number of loci necessary to be in a
susceptible state in order to confer susceptibility to MS
is smaller for patients who carry the HLA DRB1*1501
allele compared to susceptible individuals who don’t
carry this allele (Additional File 1; Appendix S1; Section
4). Using Equations (79) and (80) to estimate this differ-
ence, Table 15 shows the estimated number of loci at
different combinations of (n), (x), and (r). Notably,
within the solution space of (11 ≤ n ≤ 18) and (r ≥ 2),
even though there is a small difference in the average
number of loci required between the two sub-groups,
the estimate for (n) is exactly the same for both, indicat-
ing that this difference is quite small (i.e., less than 1
locus). Even if one makes the assumption that only indi-
viduals who are homozygous for the HLA DRB1*1501
allele require fewer loci to be in a susceptible state, the
difference in the estimated value of (n)b e t w e e ns u b -
groups within this solution space is still only about 1
locus.
Discussion and conclusions
This paper explores the genetic basis of MS pathogen-
esis through the lens of a mathematical model of genetic
susceptibility and a critical analysis of the currently
available epidemiological information about this illness.
This is not to downplay the importance of environmen-
tal factors in disease pathogenesis. Indeed, these factors
were the principal focus of previous work [10]. Rather,
the focus of this paper is on the attempt to understand,
not the genes that lead to MS susceptibility but, rather,
the basis and importance of genetic susceptibility to this
illness.
Several results seem particularly noteworthy. In earlier
publications, the critical environmental factors have
been suggested to be “population wide “ exposures
[10,22-27]. Intriguingly, a similar conclusion can be
reached by a mathematical analysis, in which that these
environmental exposures (whatever they are) can be
shown to be extremely common events [10]. By con-
trast, the genetics of MS seems to be of critical impor-
tance with regard to disease pathogenesis. Thus, the
analysis presented in this manuscript demonstrates that
the large majority of individuals who develop MS (possi-
bly all) must have, in part, a genetic basis for their dis-
ease. Moreover, to underscore the importance of genetic
susceptibility to disease pathogenesis, the mathematical
analysis of the present manuscript demonstrates that,
under any circumstance, only a tiny fraction of the gen-
eral population (<2.2%) is genetically susceptible to get-
ting this illness. Finally, the derived model demonstrates
that the possibilities for the number of susceptibility loci
(and the number of involved loci necessary to confer
that susceptibility) are quite limited (Tables 4, 5, 6, 7, 8,
9, 10, and 11). Indeed, it seems that genetic susceptibil-
ity is, by far, the most important factor in disease patho-
genesis. Thus, whereas environmental factors (while
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Page 22 of 28Table 13 (9) “Closeness of Fit” Calculations
Number of Susceptibility Genes Required (n)
5 1 01 11 21 31 41 5
Frequency of Susceptibility (r) Closeness of Fit (Target ≤4.0)
r = 0.25 24,106 29,422 28,838 28,228 29,694 29,258 28,805
r = 0.33 19,148 4,872 5,600 4,166 4,788 5,416 4,150
r = 0.5 2,139 459 555 451 320 378 189
r = 1 789 90 43.9 39.7 18.9 17.7 9.4
r = 2 394 21.4 12.1 6.9 3.3 2.4 2.5
r = 4 337 9.9 4.4 2.2 1.7 2.1 3.0
r = 8 286 6.8 3.1 1.9 2.3 3.4 4.4
r = 16 262 5.8 2.8 2.4 3.3 4.6 5.8
Number of Susceptibility Genes Required (n)
16 17 18 30 40 50 60
Frequency of Susceptibility (r) Closeness of Fit (Target ≤ 4.0)
r = 0.25 31,198 30,935 31,545 31,749 32,041 32,713 32,776
r = 0.33 3,137 3,593 4,106 1,459 1,280 885 2,042
r = 0.5 228 114 140 21.4 18.3 18.7 38.0
r = 1 5.9 6.2 4.7 8.5 10.6 11.8 11.6
r=2 3.0 3.6 4.2 10.9 13.5 14.9 12.7
r=4 4.0 5.1 6.3 13.2 15.5 16.8 14.9
r = 8 5.5 6.8 8.0 14.7 16.7 17.7 16.2
r = 16 6.8 8.1 9.4 15.6 17.3 18.2 18.3
* (Targets are in bold; optimal fit is underlined)
* Calculated as the sum of the squared percent deviations from published epidemiological observations (E) of the high (H) and low (L) estimates derived from
the model for non-twin siblings, parents/children, offspring of conjugal MS couples, and second and third degree relatives of MS probands. For each category,
this squared percent deviation is defined as: [(H - E)/E + (L - E)/E]
2
Table 14 (10) The Estimated Prevalence and the Number of Loci (n) for susceptible genotypes that include the HLA
DRB1*1501 allele
Estimated Number of Susceptibility Genes Required (n) for all Loci
11 12 13 14 15 16 17
Frequency of Susceptibility (r) Estimated Prevalence of HLA DRB1*1501 in an MS Population (unadjusted; OR ≈ 2.21)
r = 0.25 0.25 0.26 0.24–0.26 0.24–0.26 0.24–0.26 0.25 0.25
r = 0.33 0.32–0.37 0.33–0.39 0.35 0.32–0.36 0.33–0.37 0.34–0.38 0.34
r = 0.5 0.39–0.42 0.38–0.44 0.39–0.42 0.39–0.41 0.39–0.42 0.38–0.41 0.40–0.42
r = 1 0.42–0.44 0.41–0.43 0.41–0.44 0.41–0.43 0.41–0.43 0.42–0.44 0.41–0.43
r = 2 0.42–0.44 0.41–0.44 0.41–0.44 0.42–0.43 0.41–0.43 0.42–0.43 0.42–0.43
r = 4 0.42–0.44 0.42–0.44 0.42–0.44 0.41–0.43 0.42–0.43 0.42–0.43 0.42–0.43
r=8 0.42–0.44 0.42–0.44 0.41–0.43 0.42–0.43 0.42–0.43 0.41–0.43 0.42–0.43
r=1 6 0.42–0.44 0.42–0.44 0.42–0.43 0.42–0.43 0.42–0.43 0.42–0.43 0.41–0.43
Frequency of Susceptibility (r) Odd Ratios for Recessive non-HLA DRB1 Loci (after adjustment of HLA to OR = 3.34)
r = 0.25 1.21 1.23 1.05–1.23 1.05–1.27 1.07–1.29 1.07 1.08
r = 0.33 1.57–2.03 1.66–2.15 1.66–2.15 1.51–1.82 1.57–1.91 1.64–2.00 1.70
r = 0.5 1.88–2.15 1.79–2.30 1.79–2.30 1.82–2.01 1.91–2.12 1.84–2.01 1.92–2.11
r = 1 1.86–2.05 1.82–1.98 1.82–1.98 1.82–1.96 1.85–1.98 1.88–2.01 1.84–1.96
r = 2 1.75–1.85 1.73–1.85 1.73–1.85 1.75–1.83 1.74–1.84 1.74–1.84 1.75–1.82
r = 4 1.65–1.78 1.66–1.75 1.66–1.75 1.65–1.74 1.66–1.74 1.66–1.74 1.66–1.73
r=8 1.60–1.69 1.60–1.69 1.60–1.69 1.60–1.67 1.60–1.67 1.60–1.67 1.61–1.66
r=1 6 1.56–1.64 1.56–1.64 1.56–1.64 1.56–1.63 1.56–1.62 1.57–1.62 1.56–1.62
(Bold and underlined as designated for “Closeness of Fit” calculations in Table 8)
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[10,22-27], only a very small fraction of the general
population are genetically capable of getting the disease,
regardless of what occurs to them during life. This con-
clusion is not altered at all by the recent report of Bar-
anzini and co-workers [31], which reported that there
were no genetic or epigenetic differences between
elderly monozygotic twins who were clearly discordant
for MS. This finding is anticipated. Even if everyone
who developed MS had to be genetically susceptible
(and as both MZ twins will be if one has MS), the
expected concordance rate in MZ twins is still only 25%
in the northern North America and northern Europe.
This study only serves to underscores the importance of
an environmental contribution to MS pathogenesis - a
conclusion that was clearly evident decades prior to this
publication [2-11,22-27].
A previous paper also explored a mathematical model
of MS Genetics in order to determine both the number
of risk alleles required and their allelic frequency [32].
In this paper, the author approached the problem by
using observed value for the lifetime risk of MS [P(MS)]
and the monozygotic-twin concordance risk (CRMZ),
together with different numbers of risk alleles with dif-
ferent frequencies, to predict the recurrence risk in both
first and second degree relatives of an MS proband.
Conceptually, this author’s view of MS susceptibility is
that MS risk increases either with the number of risk
alleles in an additive or a multiplicative manner or as a
step function where (in the case of 10 total alleles) the
r i s kf o r6o rf e w e ra l l e l e sw a s0a n dt h er i s kf o r7o r
more alleles was 0.25 (i.e., the CRMZ). His conclusion
was that the best fit with existing data was for autoso-
mal dominant models having either a strong interaction
between the different loci, in which risk increases
rapidly with each additional disease allele or, better yet,
a step function [32]. When 10 loci are present, the alle-
lic frequency of the susceptibility alleles was calculated
to be (0.15 - 0.31). The author then explored the impact
of changing the number of presumed risk alleles (in
models using a step function where the step occurred at
100%, 67% and 33% of the number of alleles). In each
case, the allelic frequency was adjusted so that the pre-
dicted population probability of MS [P(MS)] was always
0.2%. Using this strategy, the author reported that four
different models fit the observed recurrence risk data.
Thus, dominant models in which 100% of 6 risk alleles
were required for susceptibility, dominant models with 9
or more risk alleles and 67% required, dominant models
with 15 or more risk alleles and 33% required, and a
recessive model in which 100% of 2 or 3 risk alleles
were required, all fit the data. Moreover, using this
model, the author found no upper limit to the number
of alleles possible although, with an increasing number,
the allelic frequencies increased toward 1.0 [32].
In many ways this earlier model [32] is a subset of the
model proposed here. Thus, following the argument in
Section 1, this model would still require there to be a
Table 15 (11) The estimated Number of Loci (n) in for Genotypes including or not including HLA DRB1*1501
Estimated Number of Susceptibility Genes Required (n) for all Loci
11 12 13 14 15 16 17
Frequency of Susceptibility (r) Estimated (n) the for Genotypes including HLA DRB1*1501
r = 0.25 3 3 3 3 3 3 3
r = 0.33 3 - 10 3 - 11 11 - 11 3 - 13 11 - 14 14 - 15 15
r = 0.5 10 - 11 11 - 12 12 - 13 13 - 14 14 - 15 15 - 16 17
r = 1 1 11 21 31 41 51 6 1 7
r=2 1 1 1 2 13 14 15 16 17
r=4 1 1 12 13 14 15 16 17
r=8 11 12 13 14 15 16 17
r=1 6 11 12 13 14 15 16 17
Frequency of Susceptibility (r) Estimated (n) the for Genotypes not including HLA DRB1*1501
r = 0.25 12 13 14 - 15 15 - 16 16 - 17 18 19
r = 0.33 11 - 12 12 - 13 14 15 15 - 16 16 - 17 18
r = 0.5 11 12 13 14 15 16 17
r = 1 1 11 21 31 41 51 6 1 7
14 - 15r = 2 11 12 13 14 15 16 17
r=4 1 1 12 13 14 15 16 17
r=8 11 12 13 14 15 16 17
r=1 6 11 12 13 14 15 16 17
(Bold and underlined as designated for “Closeness of Fit” calculations in Table 8)
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in order for an individual to be genetically susceptible.
Moreover, the notion of a step function (going suddenly
from non-susceptibility to susceptibility once a certain
number of risk alleles are present) is common to both
schemes. However, in the previous model, this step
function was inferred from the “closeness of fit” analysis
of the predicted recurrence rates whereas, in the present
paper, it is used as a convenience to describe a much
more complicated and interactive underlying susceptibil-
ity structure (see Section 1). In addition, there is no pro-
vision in the previous model for a possible difference in
penetrance of different combinations of risk alleles.
Neither of these differences, however, is critical and, in
fact, they are both likely to be of no importance
whatsoever.
Rather, the critical difference between the models is
that the previous model is unbounded precisely because
it is has not been tied securely to the epidemiological
realities of MS and because of its conceptualization of
susceptibility seems biologically unlikely. For example,
the author concludes that one possibility is a recessive
model in which 2 or 3 risk alleles are present and all are
required. Clearly, however, such a model is untenable.
First, the HLA DRB1*1501 allele is an established risk
allele for MS and it is known to be “dominant” in sense
that both heterozygous and homozygous states confer
susceptibility [12-15]. Consequently, not all risk alleles
can be recessive. Second, if a 100% of anything was
required, then every patient with MS would be in a sus-
ceptible allelic state at the HLA DRB1 locus, a circum-
stance which is claimed by no one. Thus, the previous
model has failed to incorporate the known epidemiolo-
gical information about the only allele (HLA
DRB1*1501), which has been securely linked to MS sus-
ceptibility. Third, and most importantly, the cutoffs of
100%, 67% and 33% for the step function are arbitrary.
In and of itself, the use of arbitrary cut-points makes lit-
tle difference and, as the author states (somewhat con-
fusingly), other cut-points were also explored. Rather, it
is the use of such cut-points, in the first place, that indi-
cates a fundamental conceptual difference in the nature
of MS susceptibility between the two approaches. Thus,
in the previous model [32], MS susceptibility is held,
not to be the result of an individual possessing a specific
combination of susceptibility alleles, but rather, to be
the result of possessing a certain fraction of the total
number such alleles. Naturally, in such a circumstance,
because the total number of possible risk alleles is
unbounded (other than by the entire genome), so too is
the number of alleles required for MS susceptibility.
Naturally, also, the allelic frequency of these putative
susceptibility alleles increases as their number increases
in order to maintain the population prevalence at 0.2%.
By contrast, in the present paper, the genetic suscept-
ibility to developing MS is conceptualized as occurring
when, from amongst a total of (x + 1) susceptibility loci
(haplotypes) spread throughout the genome, an indivi-
dual possesses a specific combination of some of these
loci, each of which is in a specific susceptible state.
Although, at each locus, there may be more than one
“susceptibility” gene and, for any gene, there may be
more than one “susceptibility” allele, the net effect of
the interaction of these different genes and different
alleles at a particular locus is presumed to put this locus
into a “susceptible” state or not. Moreover, different spe-
cific combinations of different numbers of these sus-
ceptibility loci each having specific “susceptibility
genotypes” are envisioned to produce susceptibility and
the entire set of such “susceptible” genetic combinations
is taken to define the subset of individuals in the general
population who could potentially get MS in the right
environmental circumstances. If an individual does not
possess one of these susceptible genetic combinations,
then they cannot get MS regardless of what environ-
mental events they experience in their lives. Alterna-
tively, of course, it is possible that only some (but not
all) of MS is genetic (in the sense described above) and
that some individuals may get this illness through a
purely environmental mechanism. Nevertheless, the evi-
dence (such as it exists) suggests that the vast majority
(and likely all) cases of MS are the result of a genetically
susceptible individual experiencing a sufficient (but
complex) environmental exposure, which includes mul-
tiple different events occurring at different times during
t h e i rl i f e[ 1 0 ] .T h ea v a i l a b l ee v i d e n c ea l s os u g g e s t s
strongly that genetic susceptibility to MS is a rare
occurrence. Thus, as noted above, only 2.2% or less of
the general population is susceptible to getting MS.
Even among individuals who carry the HLA DRB1*1501
allele, the probability of being susceptible to getting MS
is still only ~2.6% (Additional File 1; Appendix S1; Sec-
tion 4).
As discussed in the Introduction, this conceptualiza-
tion reflects a binary view of genetic susceptibility. This
is not, however, a fundamental assumption of the
model. Rather, the binary nature of model is a conse-
quence of the concept of susceptibility. For example, if
everyone is genetically susceptible, then the influence of
genetic factors is to alter the penetrance of the different
genotypes. By contrast, if some individual are not sus-
ceptible while others are, then susceptibility is binary,
not because of the model but because of the nature of
susceptibility. Importantly, in the model, even though
susceptibility was conceived as binary, this was not
forced into the final result. Thus the term P(G) was
unconstrained and could have been 100%. The limit of
[P(G) ≤ 2.2%] was set by the constraint of
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ent to the model.
Placed into this context, the model derived in this
manuscript provides considerable insight into the nature
of the genetic basis for MS. Indeed, the current epide-
miological observations of (h = 0.24; hm = 0.55; P(MS) =
0.0015; and Pt0 =P t 1 = 0.25), suggest that the upper
limit for the average number of susceptibility loci (n)
that need to be in a susceptible state for an individual
to be susceptible to getting MS is (11 ≤ n ≤ 18). More-
over, the total number of non-HLA DRB1 loci (x)t h a t
contribute to susceptibility seems to be between 50 and
200, and that the frequency of susceptibility at these loci
is approximately (h/r ≤ 0.12) or (r ≥ 2 ) .I nf a c t ,t h e
genetic configuration that best fits these epidemiological
observations, the current prevalence estimates, and the
concordance data for non-twin siblings, parents and
children, children of conjugal MS couples, second
degree relatives, and third degree relatives occurs when
80% of the loci are recessive and at (x = 100-107; n =
13; and r = 4). Indeed, the prevalence and recurrence
risks predicted by these particular values match the
actual epidemiological observations quite closely (Table
13). It is of note that these predicted recurrence risks
have been calculated using a penetrance estimate that
has been down-weighted from the identical-twin con-
cordance rate because of the apparently important influ-
ence of the shared intra-uterine or early post-natal
environment [10]. If an unadjusted penetrance had been
used, all of the estimated recurrence rates would have
been approximately double and none of models (reces-
sive, dominant, or mixed) would have provided a good
fit with the actual epidemiological data. Such a finding,
independently, tends to validate the importance of the
intra-uterine and/or early post-natal environment in MS
pathogenesis.
It also seems likely that either the large majority of the
(x) susceptibility loci must be “recessive” (in the sense
described in the Additional File 1; Appendix S1) or
there must be more than one susceptibility gene present
at each susceptibility locus and that these genes must
combine in such a way that only a small fraction of the
possible combinations produce a susceptible state at the
locus (Additional File 1; Appendix S1). There are three
reasons for this conclusion. First, and most important,
the predicted recurrence risk for MS in siblings for a
single dominant gene (even one with multiple different
susceptibility alleles) seems too high to explain the epi-
demiological observations (Tables 4, 5 and 11). Second,
the optimal fit for the predicted with the observed data
occurs when only 20% of the loci are assumed to be
“dominant” (Table 8). Third, the observed odds ratios
(OR = 1.1 - 1.3) for different candidate genes at non-
HLA DRB1 loci in genome-wide association studies
[12-15] seems too small to be easily explained by the
alterations of the parameters of (h), (hm), and (Pt1)f o r
“dominant” alleles. In addition, altering these parameters
generally results in a Closeness of Fit estimates, which
are both too high and worse compared to the estimate
using the observed parameter values of (h = 0.24), (hm =
0.55), and (Pt1 = 0.25). This last piece of evidence, how-
ever, may not make a compelling argument because the
odds ratio can also be markedly affected by the use of
single SNPs to identify alleles. Thus, depending upon
the exact nature of the relationship between the state of
the DNA at the SNP location and the polymorphic
alleles of any particular susceptibility gene, the observed
odds ratio (even for dominant alleles) can be dramati-
cally reduced (see Additional File 1; Appendix S1; Sec-
tion 5).
One difficulty with the use of genome-wide associa-
tion screens to identify susceptibility loci is that, due to
multiple statistical comparisons and random sampling
error, all such screens will be quite susceptible to both
the false positive and the false negative identification of
loci. If the bar for association is set too low, false posi-
tives will greatly outnumber false negative identifica-
tions. By contrast, if the bar is set too high, false
negatives will greatly outnumber false positive identifica-
tions. Compounding the difficulties of sorting out false
positive and false negative identifications, is the fact that
the distinction between a true susceptibility locus and a
disease-modifying locus will be problematic. Thus,
although only (x + 1) susceptibility loci are present in
t h ee n t i r eg e n o m e ,t h e r em a yb em a n yo t h e rl o c it h a t
can modify the clinical expression of MS by either by
changing the actual penetrance of MS in susceptible
individuals or by changing the apparent penetrance, for
example, by altering the disease severity or the pheno-
type of the illness.
Regardless of the mechanism however, on a genome-
wide association screen, any locus that has such an
effect on penetrance (real or otherwise) will appear to
be positively or negatively associated with the illness.
For example, if the presence of a particular allele of a
particular gene (not involved in MS susceptibility)
doubled the penetrance of MS for all susceptible combi-
nations, the odds ratio for an association of this allele
with MS would be (2.0) and highly significant, despite
the fact that this allele would not be a “susceptibility”
allele and the locus that harbored this allele would not
be a “susceptibility” locus in the sense defined earlier
(i.e., this would be a false association). Moreover,
because the model places no constraints on the possible
number of these disease-modifying loci, many of the
observed associations (even highly significant and/or
well replicated ones) may have a substantial probability
of representing a false association with the genetic
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ity loci and disease modifying loci will be identified
equally well by genome-wide screens, unraveling the
two will not be possible using this approach. One possi-
ble method for establishing that an MS-associated allele
was a true susceptibility allele (e.g., the HLA DRB1*1501
allele) would be to demonstrate that it doesn’ta l t e rt h e
penetrance sufficiently to account for the observed odds
ratio on genome-wide screens (e.g., Table 3). For most
associations, however, such a method will be difficult
both because the available identical-twin data to assess
penetrance differences is limited and because the
observed odds ratios for candidate genes are typically
small [15].
Considering the results of several genome-wide asso-
ciation screens [2,12-15,33,34], it has been relatively
easy to identify the HLA DRB1 locus (haplotype) in gen-
eral, and the 1501 allele in particular, as associated with
MS. In addition, the observed odds ratio for an associa-
tion of this chromosomal region with MS has been
much larger (and much more consistent) compared to
other potential candidate loci [12-15]. Indeed, the
strength and uniqueness of this association has led
many investigators to conclude that genetic variation
within this chromosomal region is principally responsi-
ble for genetic susceptibility to MS [2,12-15]. Considera-
tion of the model proposed here and some of the
observations made from it, however, might be taken to
raise questions about such a conclusion. First, the HLA
DRB1 locus (haplotype) seems to be only one among a
hundred or more loci that are involved in MS suscept-
ibility. Second, although the frequency of having at least
one copy of the HLA DRB1*1501 allele in the general
population is approximately four times the frequency of
susceptibility at non-HLA DRB1 loci, the penetrance of
susceptible genotypes that include this allele is no differ-
ent from those that don’t (Table 3). Third, although the
number of other susceptibility loci that need to be
involved is smaller when this allele is present, the actual
d i f f e r e n c ei sl e s st h a n1l o c u s( T a b l e1 5 ) .I nc i r c u m -
stances where a genetically susceptible genotype requires
involvement of 11-18 total loci (Table 4), this difference
seems negligible. Fourth, almost a half of the genetically
susceptible individuals, lack this allele entirely. More-
over, only a small fraction of those individuals who
carry this allele (≤ 5.2%) are even susceptible to getting
this MS in the first place (Additional File 1; Appendix
S1; Section 4). In this context, the apparent predomi-
nance of the HLA DRB1*1501 allele in MS pathogenesis
seems likely related to three factors (see Additional File
1; Appendix S1; Section 5). First, this allele is one of the
uncommon dominant susceptibility alleles and these
have greater associated odds ratios than recessive alleles.
Second, susceptible genotypes including this allele have
a slightly smaller number of involved loci compared to
those genotypes without it, a circumstance that will
inflate the observed odds ratio for the HLA locus but
n o tf o rt h en o n - H L Al o c i .A n d ,t h i r d ,t h eu s eo fS N P s
to represent the allelic structure of the genome will
markedly reduce the observed odds ratio for many (pos-
sibly most) true susceptibility non-HLA loci regardless
of whether they are dominant or recessive.
This might also help to explain the observation that
some of the identified SNPs have relative allelic frequen-
cies (RAFs) for some of the identified susceptibility loci,
which are unexpectedly high [13]. For example the
interleukin 7 receptor (ILR7) gene using SNP
(rs6897932) has an RAF of (0.75), whereas the IL2
receptor alpha (IL2RA) gene using SNPs (rs12722489
and rs2104286) has RAFs of (0.85) and (0.75) respec-
tively. Several phenomenon may account for this appar-
ent paradox. First, if any of the these SNPs tagged more
than one allele (see Additional File 1; Appendix S1; Sec-
tion 5), this would increase the “apparent” allelic fre-
quency of the true susceptibility allele. Indeed, the
occurrence of different RAFs for the same locus (as is
seen above for IL2RA gene) presumably indicates that
the allelic structure is not simple even though, in this
case, the difference is quite small. Second, even if the
SNP is located in the coding region of a particular gene
and is known to cause a functional change in the coded
protein by introducing a stop codon or a non-synon-
ymous amino acid substitution, altering splice sites, or
changing the binding characteristics of regulatory mole-
cules (e.g. 33, 34), this does not prove either that this
functional change is what caused susceptibility or that
this gene is involved with susceptibility. Even in this cir-
cumstance, the association only identifies the region of
the genome wherein susceptibility resides. Third, even
in the circumstance where the SNP association has
identified the correct gene and causes a functional
change in the coded protein, this still falls short of prov-
ing causation. It could be that a second alteration in this
gene, together with the identified SNP, identifies the
true susceptibility allele (see Additional File 1; Appendix
S1; Section 5). And fourth, the method of genome-wide
association screening is set-up to identify associations
with SNPs of high frequency (i.e., major alleles) and to
ignore minor alleles.
Indeed, the fact that the genes identified to date (with
the exception of the HLA DRB1 locus produce such low
ORs [2,12-15,33,34], especially in the circumstance
where the genetics of MS is, by far, the most important
contributor to disease incidence, makes it seem likely
that some, perhaps all, of these physiologic mechanisms
are occurring. Clearly, we have a long way to go to
understand the specifics of MS susceptibility. Neverthe-
less, gaining some insight to the number of susceptibility
Goodin BMC Neurology 2010, 10:101
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Page 27 of 28loci involved, the number of loci needed to be in a sus-
ceptible state, and the average frequency of susceptibility
at these susceptibility loci represents progress.
Additional material
Additional file 1: Appendix S1. Mathematical derivations used for the
development of the model.
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